Implantable medical device with pressure sensor

Description

TECHNICAL FIELD

The present disclosure generally relates to implantable medical devices and more particularly to implantable medical devices with pressure sensors BACKGROUND Implantable medical devices are commonly used to perform a variety of functions, such as to monitor one or more conditions and/or delivery therapy to a patient. In some cases, an implantable medical device may deliver neurostimulation therapy to a patient. In some cases, an implantable medical device may simply monitor one or more conditions, such as pressure, acceleration, cardiac events, and may communicate the detected conditions or events to another device, such as another implantable medical device or an external programmer.

In some cases, an implantable medical device may be configured to deliver pacing and/or defibrillation therapy to a patient. Such implantable medical devices may treat patients suffering from various heart conditions that may result in a reduced ability of the heart to deliver sufficient amounts of blood to a patient's body. In some cases, heart conditions may lead to rapid, irregular, and/or inefficient heart contractions. To help alleviate some of these conditions, various devices (e.g., pacemakers, defibrillators, etc.) may be implanted into a patient's body. When so provided, such devices can monitor and provide therapy, such as electrical stimulation therapy, to the patient's heart to help the heart operate in a more normal, efficient and/or safe manner. In some cases, a patient may have multiple implanted devices that cooperate to monitor and/or provide therapy to the patient's heart.

SUMMARY

The present disclosure generally relates to implantable medical devices and more particularly to implantable medical devices with pressure sensors.

In a first example, a leadless cardiac pacemaker (LCP) may be configured to sense cardiac activity and to deliver pacing therapy to a patient's heart. The LCP may comprise a housing having a proximal end and a distal end, a first electrode secured relative to the housing and exposed to the environment outside of the housing, a second electrode secured relative to the housing and exposed to the environment outside of the housing, a diaphragm that is exposed to the environment outside of the housing, the diaphragm is responsive to an external pressure applied to the diaphragm by the environment outside of the housing, a piezoelectric membrane having a first pressure sensor electrode and a second pressure sensor electrode, the piezoelectric membrane may be configured to generate an electrical voltage between the first pressure sensor electrode and the second pressure sensor electrode in response to a pressure change applied to the diaphragm, the electrical voltage representative of a change in external pressure applied to the diaphragm, and circuitry in the housing operatively coupled to the first electrode and the second electrode of the LCP, and also operatively coupled to the first pressure sensor electrode and the second pressure sensor electrode, the circuitry may be configured to deliver a pacing therapy to the patient's heart via the first electrode and the second electrode of the LCP, wherein the pacing therapy is dependent, at least in part, on the electrical voltage generated by the piezoelectric membrane and that is representative of the change in external pressure applied to the diaphragm.

Alternatively or additionally to any of the examples above, in another example, the circuitry may be configured to detect a pressure pulse by monitoring the electrical voltage generated between the first pressure sensor electrode and the second pressure sensor electrode by the piezoelectric membrane.

Alternatively or additionally to any of the examples above, in another example, the diaphragm may have an interior surface that faces toward an interior of the housing, and the piezoelectric membrane may be spaced a distance from the interior surface of the diaphragm and may be operatively coupled to the interior surface of the diaphragm via an incompressible fluid.

Alternatively or additionally to any of the examples above, in another example, the incompressible fluid may be in a fluid cavity that is at least partially defined by the interior surface of the diaphragm and may be in fluid communication with both the interior surface of the diaphragm and the piezoelectric membrane, wherein the fluid cavity may be configured to communicate a pressure applied to the incompressible fluid by the diaphragm to the piezoelectric membrane.

Alternatively or additionally to any of the examples above, in another example, the diaphragm of the housing may include one or more contours.

Alternatively or additionally to any of the examples above, in another example, the circuitry may be configured to detect a change in pressure in a first chamber of the heart caused by a contraction of a second chamber of the heart.

Alternatively or additionally to any of the examples above, in another example, the first chamber may be a ventricle, and the second chamber may be the corresponding atrium.

Alternatively or additionally to any of the examples above, in another example, the diaphragm may be integrally formed with the housing.

Alternatively or additionally to any of the examples above, in another example, the diaphragm may be hermetically sealed to the housing.

Alternatively or additionally to any of the examples above, in another example, the LCP may further comprise a fixation member at the distal end of the housing for fixing the distal end of the housing to an implant site, and wherein the diaphragm of the housing is adjacent the proximal end of the housing.

Alternatively or additionally to any of the examples above, in another example, the housing may include an elongated body with a distal end surface facing distally and a proximal end surface facing proximally, wherein the diaphragm of the housing may be situated on the proximal end surface of the housing.

Alternatively or additionally to any of the examples above, in another example, the diaphragm and/or piezoelectric membrane may be formed to maximize the dynamic change of the diaphragm and/or piezoelectric membrane when implanted.

Alternatively or additionally to any of the examples above, in another example, the LCP may further comprise an anti-thrombogenic coating disposed over the diaphragm of the housing.

In another example, a leadless cardiac pacemaker (LCP) may be configured to sense cardiac activity and to deliver pacing therapy to a patient's heart. The LCP may comprise a housing having a proximal end and a distal end, a first electrode secured relative to the housing and exposed to the environment outside of the housing, a second electrode secured relative to the housing and exposed to the environment outside of the housing, a diaphragm that is exposed to the environment outside of the housing, the diaphragm is responsive to an external pressure applied to the diaphragm by the environment outside of the housing, a piezoelectric membrane having a first pressure sensor electrode and a second pressure sensor electrode, the piezoelectric membrane may be configured to generate an electrical voltage between the first pressure sensor electrode and the second pressure sensor electrode in response to a pressure change applied to the diaphragm, the electrical voltage representative of a change in external pressure applied to the diaphragm, and circuitry in the housing operatively coupled to the first electrode and the second electrode of the LCP, and also operatively coupled to the first pressure sensor electrode and the second pressure sensor electrode, the circuitry may be configured to deliver a pacing therapy to the patient's heart via the first electrode and the second electrode of the LCP, wherein the pacing therapy is dependent, at least in part, on the electrical voltage generated by the piezoelectric membrane and that is representative of the change in external pressure applied to the diaphragm.

Alternatively or additionally to any of the examples above, in another example, the diaphragm of the housing may include one or more contours.

Alternatively or additionally to any of the examples above, in another example, the first chamber may be a ventricle, and the second chamber may be the corresponding atrium.

Alternatively or additionally to any of the examples above, in another example, the diaphragm may be integrally formed with the housing.

Alternatively or additionally to any of the examples above, in another example, the diaphragm may be hermetically sealed to the housing.

In another example, a leadless cardiac pacemaker (LCP) may be configured to sense cardiac activity and to pace a patient's heart. The LCP may comprise a housing having a proximal end and a distal end, a first electrode secured relative to the housing and exposed to the environment outside of the housing, a second electrode secured relative to the housing and exposed to the environment outside of the housing, the housing having a diaphragm that is exposed to the environment outside of the housing, the diaphragm is responsive to a pressure applied to the diaphragm by the environment outside of the housing, a piezoelectric material operatively coupled to the diaphragm of the housing for detecting a deflection in the diaphragm by generating charge that is representative of the pressure applied to the diaphragm by the environment outside of the housing, and circuitry in the housing in operative communication with the first electrode, the second electrode and the piezoelectric material, the circuitry may be configured to deliver a pacing therapy to the patient's heart via the first electrode and the second electrode, wherein the pacing therapy is dependent, at least in part, on the charge that is generated by the piezoelectric material and that is representative of the pressure applied to the diaphragm by the environment outside of the housing.

Alternatively or additionally to any of the examples above, in another example, the circuitry may be configured to detect a pressure pulse by monitoring the charge generated by the piezoelectric material.

Alternatively or additionally to any of the examples above, in another example, the first chamber may be a ventricle, and the second chamber may be the corresponding atrium.

In another example, an implantable medical device (IMD) may comprise a housing having a proximal end and a distal end, a first electrode secured relative to the housing and exposed to the environment outside of the housing, a second electrode secured relative to the housing and exposed to the environment outside of the housing, the housing having a diaphragm that is exposed to the environment outside of the housing, the diaphragm is responsive to a pressure applied to the diaphragm by the environment outside of the housing, a piezoelectric membrane disposed on an inner surface of the diaphragm, the piezoelectric membrane generating a charge in response to the pressure applied to the diaphragm by the environment outside of the housing, and circuitry in the housing in operative communication with the first electrode, the second electrode and the piezoelectric membrane, the circuitry may be configured to deliver an electrostimulation therapy to the patient's heart via the first electrode and the second electrode, wherein the therapy is dependent, at least in part, on the charge that is generated by the piezoelectric membrane and that is representative of the pressure applied to the diaphragm by the environment outside of the housing.

Alternatively or additionally to any of the examples above, in another example, the piezoelectric membrane may comprise polyvinylidene fluoride (PVDF).

Alternatively or additionally to any of the examples above, in another example, the circuitry may be configured to detect a change in pressure in a first chamber of a heart caused by a contraction of a second chamber of the heart.

The above summary is not intended to describe each embodiment or every implementation of the present disclosure. Advantages and attainments, together with a more complete understanding of the disclosure, will become apparent and appreciated by referring to the following description and claims taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

The disclosure may be more completely understood in consideration of the following description of various illustrative embodiments in connection with the accompanying drawings, in which:

FIG. 1 is a schematic block diagram of an illustrative leadless cardiac pacemaker (LCP) according to one example of the present disclosure;

FIG. 2 is a schematic block diagram of another medical device (MD), which may be used in conjunction with an LCP 100 (FIG. 1) in order to detect and/or treat cardiac arrhythmias and other heart conditions;

FIG. 3 is a schematic diagram of an exemplary medical system that includes multiple LCPs and/or other devices in communication with one another;

FIG. 4 is a schematic diagram of an exemplary medical system that includes an LCP and another medical device, in accordance with yet another example of the present disclosure;

FIG. 5 is a schematic diagram of an exemplary medical system that includes an LCP and another medical device, in accordance with yet another example of the present disclosure;

FIG. 6 is a side view of an illustrative LCP;

FIG. 7A is a plan view of an example LCP implanted within a heart during ventricular filling;

FIG. 7B is a plan view of an example LCP implanted within a heart during ventricular contraction;

FIG. 8 is a graph showing example pressures and volumes within the heart over time;

FIG. 9 is a schematic cross-sectional view of an illustrative LCP;

FIG. 10 is a schematic cross-sectional view of an illustrative pressure sensor for use with an implantable medical device (IMD) such as an LCP;

FIG. 11 is a schematic cross-sectional view of an illustrative pressure sensor for use with an IMD such as an LCP;

FIG. 12 is a schematic cross-sectional view of a proximal end portion of another illustrative LCP;

FIG. 13 is a schematic cross-sectional view of a proximal end portion of another illustrative LCP;

FIG. 14 is a schematic cross-sectional view of a proximal end portion of another illustrative LCP; and

FIG. 15 is a schematic cross-sectional view of a proximal end of another illustrative LCP.

While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit aspects of the disclosure to the particular illustrative embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.

DESCRIPTION

The following description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The description and the drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the disclosure. While the present disclosure is applicable to any suitable implantable medical device (IMD), the description below uses pacemakers and more particularly leadless cardiac pacemakers (LCP) as particular examples.

A normal, healthy heart induces contraction by conducting intrinsically generated electrical signals throughout the heart. These intrinsic signals cause the muscle cells or tissue of the heart to contract. This contraction forces blood out of and into the heart, providing circulation of the blood throughout the rest of the body. However, many patients suffer from cardiac conditions that affect this contractility of their hearts. For example, some hearts may develop diseased tissues that no longer generate or conduct intrinsic electrical signals. In some examples, diseased cardiac tissues conduct electrical signals at differing rates, thereby causing an unsynchronized and inefficient contraction of the heart. In other examples, a heart may initiate intrinsic signals at such a low rate that the heart rate becomes dangerously low. In still other examples, a heart may generate electrical signals at an unusually high rate. In some cases such an abnormality can develop into a fibrillation state, where the contraction of the patient's heart chambers are almost completely de-synchronized and the heart pumps very little to no blood. Implantable medical devices, which may be configured to determine occurrences of such cardiac abnormalities or arrhythmias and deliver one or more types of electrical stimulation therapy to patient's hearts, may help to terminate or alleviate these and other cardiac conditions.

FIG. 1 depicts an illustrative leadless cardiac pacemaker (LCP) that may be implanted into a patient and may operate to prevent, control, or terminate cardiac arrhythmias in patients by, for example, appropriately employing one or more therapies (e.g., anti-tachycardia pacing (ATP) therapy, cardiac resynchronization therapy (CRT), bradycardia therapy, defibrillation pulses, or the like). As can be seen in FIG. 1, the LCP 100 may be a compact device with all components housed within the LCP 100 or directly on the housing 120. In the example shown in FIG. 1, the LCP 100 may include a communication module 102, a pulse generator module 104, an electrical sensing module 106, a mechanical sensing module 108, a processing module 110, a battery 112, and electrodes 114. The LCP 100 may include more or less modules, depending on the application.

The communication module 102 may be configured to communicate with devices such as sensors, other medical devices, and/or the like, that are located externally to the LCP 100. Such devices may be located either external or internal to the patient's body. Irrespective of the location, remote devices (i.e., external to the LCP 100 but not necessarily external to the patient's body) can communicate with the LCP 100 via the communication module 102 to accomplish one or more desired functions. For example, the LCP 100 may communicate information, such as sensed electrical signals, data, instructions, messages, etc., to an external medical device through the communication module 102. The external medical device may use the communicated signals, data, instructions and/or messages to perform various functions, such as determining occurrences of arrhythmias, delivering electrical stimulation therapy, storing received data, analyzing received data, and/or performing any other suitable function. The LCP 100 may additionally receive information such as signals, data, instructions and/or messages from the external medical device through the communication module 102, and the LCP 100 may use the received signals, data, instructions and/or messages to perform various functions, such as determining occurrences of arrhythmias, delivering electrical stimulation therapy, storing received data, analyzing received data, and/or performing any other suitable function. The communication module 102 may be configured to use one or more methods for communicating with remote devices. For example, the communication module 102 may communicate via radiofrequency (RF) signals, inductive coupling, optical signals, acoustic signals, conducted communication signals, and/or any other signals suitable for communication.

In the example shown in FIG. 1, the pulse generator module 104 may be electrically connected to the electrodes 114. In some examples, the LCP 100 may include one or more additional electrodes 114′. In such examples, the pulse generator 104 may also be electrically connected to the additional electrodes 114′. The pulse generator module 104 may be configured to generate electrical stimulation signals. For example, the pulse generator module 104 may generate electrical stimulation signals by using energy stored in a battery 112 within the LCP 100 and deliver the generated electrical stimulation signals via the electrodes 114 and/or 114′. Alternatively, or additionally, the pulse generator 104 may include one or more capacitors, and the pulse generator 104 may charge the one or more capacitors by drawing energy from the battery 112. The pulse generator 104 may then use the energy of the one or more capacitors to deliver the generated electrical stimulation signals via the electrodes 114 and/or 114′. In at least some examples, the pulse generator 104 of the LCP 100 may include switching circuitry to selectively connect one or more of the electrodes 114 and/or 114′ to the pulse generator 104 in order to select which of the electrodes 114/114′ (and/or other electrodes) the pulse generator 104 delivers the electrical stimulation therapy. The pulse generator module 104 may generate electrical stimulation signals with particular features or in particular sequences in order to provide one or multiple of a number of different stimulation therapies. For example, the pulse generator module 104 may be configured to generate electrical stimulation signals to provide electrical stimulation therapy to combat bradycardia, tachycardia, cardiac dyssynchrony, bradycardia arrhythmias, tachycardia arrhythmias, fibrillation arrhythmias, cardiac synchronization arrhythmias and/or to produce any other suitable electrical stimulation therapy. Some more common electrical stimulation therapies include bradycardia therapy, anti-tachycardia pacing (ATP) therapy, cardiac resynchronization therapy (CRT), and cardioversion/defibrillation therapy.

In some examples, the LCP 100 may not include a pulse generator 104 or may turn off the pulse generator 104. When so provided, the LCP 100 may be a diagnostic only device. In such examples, the LCP 100 may not deliver electrical stimulation therapy to a patient. Rather, the LCP 100 may collect data about cardiac electrical activity and/or physiological parameters of the patient and communicate such data and/or determinations to one or more other medical devices via the communication module 102.

In some examples, the LCP 100 may include an electrical sensing module 106, and in some cases, a mechanical sensing module 108. The electrical sensing module 106 may be configured to sense the cardiac electrical activity of the heart. For example, the electrical sensing module 106 may be connected to the electrodes 114/114′, and the electrical sensing module 106 may be configured to receive cardiac electrical signals conducted through the electrodes 114/114′. The cardiac electrical signals may represent local information from the chamber in which the LCP 100 is implanted. For instance, if the LCP 100 is implanted within a ventricle of the heart, cardiac electrical signals sensed by the LCP 100 through the electrodes 114/114′ may represent ventricular cardiac electrical signals. The mechanical sensing module 108 may include one or more sensors, such as an accelerometer, a blood pressure sensor, a heart sound sensor, a blood-oxygen sensor, a temperature sensor, a flow sensor and/or any other suitable sensors that are configured to measure one or more mechanical and/or chemical parameters of the patient. Both the electrical sensing module 106 and the mechanical sensing module 108 may be connected to a processing module 110, which may provide signals representative of the sensed mechanical parameters. Although described with respect to FIG. 1 as separate sensing modules, in some cases, the electrical sensing module 106 and the mechanical sensing module 108 may be combined into a single sensing module, as desired.

The electrodes 114/114′ can be secured relative to the housing 120 but exposed to the tissue and/or blood surrounding the LCP 100. In some cases, the electrodes 114 may be generally disposed on either end of the LCP 100 and may be in electrical communication with one or more of the modules 102, 104, 106, 108, and 110. The electrodes 114/114′ may be supported by the housing 120, although in some examples, the electrodes 114/114′ may be connected to the housing 120 through short connecting wires such that the electrodes 114/114′ are not directly secured relative to the housing 120. In examples where the LCP 100 includes one or more electrodes 114′, the electrodes 114′ may in some cases be disposed on the sides of the LCP 100, which may increase the number of electrodes by which the LCP 100 may sense cardiac electrical activity, deliver electrical stimulation and/or communicate with an external medical device. The electrodes 114/114′ can be made up of one or more biocompatible conductive materials such as various metals or alloys that are known to be safe for implantation within a human body. In some instances, the electrodes 114/114′ connected to LCP 100 may have an insulative portion that electrically isolates the electrodes 114/114′ from adjacent electrodes, the housing 120, and/or other parts of the LCP 100.

The processing module 110 can be configured to control the operation of the LCP 100. For example, the processing module 110 may be configured to receive electrical signals from the electrical sensing module 106 and/or the mechanical sensing module 108. Based on the received signals, the processing module 110 may determine, for example, occurrences and, in some cases, types of arrhythmias. Based on any determined arrhythmias, the processing module 110 may control the pulse generator module 104 to generate electrical stimulation in accordance with one or more therapies to treat the determined arrhythmia(s). The processing module 110 may further receive information from the communication module 102. In some examples, the processing module 110 may use such received information to help determine whether an arrhythmia is occurring, determine a type of arrhythmia, and/or to take particular action in response to the information. The processing module 110 may additionally control the communication module 102 to send/receive information to/from other devices.

In some examples, the processing module 110 may include a pre-programmed chip, such as a very-large-scale integration (VLSI) chip and/or an application specific integrated circuit (ASIC). In such embodiments, the chip may be pre-programmed with control logic in order to control the operation of the LCP 100. By using a pre-programmed chip, the processing module 110 may use less power than other programmable circuits (e.g., general purpose programmable microprocessors) while still being able to maintain basic functionality, thereby potentially increasing the battery life of the LCP 100. In other examples, the processing module 110 may include a programmable microprocessor. Such a programmable microprocessor may allow a user to modify the control logic of the LCP 100 even after implantation, thereby allowing for greater flexibility of the LCP 100 than when using a pre-programmed ASIC. In some examples, the processing module 110 may further include a memory, and the processing module 110 may store information on and read information from the memory. In other examples, the LCP 100 may include a separate memory (not shown) that is in communication with the processing module 110, such that the processing module 110 may read and write information to and from the separate memory.

The battery 112 may provide power to the LCP 100 for its operations. In some examples, the battery 112 may be a non-rechargeable lithium-based battery. In other examples, a non-rechargeable battery may be made from other suitable materials, as desired. Because the LCP 100 is an implantable device, access to the LCP 100 may be limited after implantation. Accordingly, it is desirable to have sufficient battery capacity to deliver therapy over a period of treatment such as days, weeks, months, years or even decades. In some instances, the battery 112 may a rechargeable battery, which may help increase the useable lifespan of the LCP 100. In still other examples, the battery 112 may be some other type of power source, as desired.

To implant the LCP 100 inside a patient's body, an operator (e.g., a physician, clinician, etc.), may fix the LCP 100 to the cardiac tissue of the patient's heart. To facilitate fixation, the LCP 100 may include one or more anchors 116. The anchor 116 may include any one of a number of fixation or anchoring mechanisms. For example, the anchor 116 may include one or more pins, staples, threads, screws, helix, tines, and/or the like. In some examples, although not shown, the anchor 116 may include threads on its external surface that may run along at least a partial length of the anchor 116. The threads may provide friction between the cardiac tissue and the anchor to help fix the anchor 116 within the cardiac tissue. In other examples, the anchor 116 may include other structures such as barbs, spikes, or the like to facilitate engagement with the surrounding cardiac tissue.

FIG. 2 depicts an example of another medical device (MD) 200, which may be used in conjunction with an LCP 100 (FIG. 1) in order to detect and/or treat cardiac arrhythmias and other heart conditions. In the example shown, the MD 200 may include a communication module 202, a pulse generator module 204, an electrical sensing module 206, a mechanical sensing module 208, a processing module 210, and a battery 218. Each of these modules may be similar to the modules 102, 104, 106, 108, and 110 of the LCP 100. Additionally, the battery 218 may be similar to the battery 112 of the LCP 100. In some examples, the MD 200 may have a larger volume within the housing 220 than LCP 100. In such examples, the MD 200 may include a larger battery and/or a larger processing module 210 capable of handling more complex operations than the processing module 110 of the LCP 100.

While it is contemplated that the MD 200 may be another leadless device such as shown in FIG. 1, in some instances the MD 200 may include leads such as leads 212. The leads 212 may include electrical wires that conduct electrical signals between the electrodes 214 and one or more modules located within the housing 220. In some cases, the leads 212 may be connected to and extend away from the housing 220 of the MD 200. In some examples, the leads 212 are implanted on, within, or adjacent to a heart of a patient. The leads 212 may contain one or more electrodes 214 positioned at various locations on the leads 212, and in some cases at various distances from the housing 220. Some of the leads 212 may only include a single electrode 214, while other leads 212 may include multiple electrodes 214. Generally, the electrodes 214 are positioned on the leads 212 such that when the leads 212 are implanted within the patient, one or more of the electrodes 214 are positioned to perform a desired function. In some cases, the one or more of the electrodes 214 may be in contact with the patient's cardiac tissue. In some cases, the one or more of the electrodes 214 may be positioned substernally or subcutaneously but adjacent the patient's heart. In some cases, the electrodes 214 may conduct intrinsically generated electrical signals to the leads 212, e.g., signals representative of intrinsic cardiac electrical activity. The leads 212 may, in turn, conduct the received electrical signals to one or more of the modules 202, 204, 206, and 208 of the MD 200. In some cases, the MD 200 may generate electrical stimulation signals, and the leads 212 may conduct the generated electrical stimulation signals to the electrodes 214. The electrodes 214 may then conduct the electrical signals and delivery the signals to the patient's heart (either directly or indirectly).

The mechanical sensing module 208, as with the mechanical sensing module 108, may contain or be electrically connected to one or more sensors, such as accelerometers, blood pressure sensors, heart sound sensors, blood-oxygen sensors, acoustic sensors, ultrasonic sensors and/or other sensors which are configured to measure one or more mechanical/chemical parameters of the heart and/or patient. In some examples, one or more of the sensors may be located on the leads 212, but this is not required. In some examples, one or more of the sensors may be located in the housing 220.

While not required, in some examples, the MD 200 may be an implantable medical device. In such examples, the housing 220 of the MD 200 may be implanted in, for example, a transthoracic region of the patient. The housing 220 may generally include any of a number of known materials that are safe for implantation in a human body and may, when implanted, hermetically seal the various components of the MD 200 from fluids and tissues of the patient's body.

In some cases, the MD 200 may be an implantable cardiac pacemaker (ICP). In this example, the MD 200 may have one or more leads, for example leads 212, which are implanted on or within the patient's heart. The one or more leads 212 may include one or more electrodes 214 that are in contact with cardiac tissue and/or blood of the patient's heart. The MD 200 may be configured to sense intrinsically generated cardiac electrical signals and determine, for example, one or more cardiac arrhythmias based on analysis of the sensed signals. The MD 200 may be configured to deliver CRT, ATP therapy, bradycardia therapy, and/or other therapy types via the leads 212 implanted within the heart or in concert with the LCP by commanding the LCP to pace. In some examples, the MD 200 may additionally be configured provide defibrillation therapy.

In some instances, the MD 200 may be an implantable cardioverter-defibrillator (ICD). In such examples, the MD 200 may include one or more leads implanted within a patient's heart. The MD 200 may also be configured to sense cardiac electrical signals, determine occurrences of tachyarrhythmias based on the sensed signals, and may be configured to deliver defibrillation therapy in response to determining an occurrence of a tachyarrhythmia. In some instances, the MD 200 may be a subcutaneous implantable cardioverter-defibrillator (S-ICD). In examples where the MD 200 is an S-ICD, one of the leads 212 may be a subcutaneously implanted lead. In at least some examples where the MD 200 is an S-ICD, the MD 200 may include only a single lead which is implanted subcutaneously, but this is not required. In some cases, the S-ICD lead may extend subcutaneously from the S-ICD can, around the sternum and may terminate adjacent the interior surface of the sternum.

In some examples, the MD 200 may not be an implantable medical device. Rather, the MD 200 may be a device external to the patient's body, and may include skin-electrodes that are placed on a patient's body. In such examples, the MD 200 may be able to sense surface electrical signals (e.g., cardiac electrical signals that are generated by the heart or electrical signals generated by a device implanted within a patient's body and conducted through the body to the skin). In such examples, the MD 200 may be configured to deliver various types of electrical stimulation therapy, including, for example, defibrillation therapy. The MD 200 may be further configured to deliver electrical stimulation via the LCP by commanding the LCP to deliver the therapy.

FIG. 3 shows an example medical device system with a communication pathway through which multiple medical devices 302, 304, 306, and/or 310 may communicate. In the example shown, the medical device system 300 may include LCPs 302 and 304, an external medical device 306, and other sensors/devices 310. The external device 306 may be any of the devices described previously with respect to MD 200. In some embodiments, the external device 306 may be provided with or be in communication with a display 312. The display 312 may be a personal computer, tablet computer, smart phone, laptop computer, or other display as desired. In some instances, the display 312 may include input means for receiving an input from a user. For example, the display 312 may also include a keyboard, mouse, actuatable (e.g., pushable) buttons, or a touchscreen display. These are just examples. The other sensors/devices 310 may be any of the devices described previously with respect to the MD 200. In some instances, the other sensors/devices 310 may include a sensor, such as an accelerometer or blood pressure sensor, or the like. In some cases, the other sensors/devices 310 may include an external programmer device that may be used to program one or more devices of the system 300.

Various devices of the system 300 may communicate via a communication pathway 308. For example, the LCPs 302 and/or 304 may sense intrinsic cardiac electrical signals and may communicate such signals to one or more other devices 302/304, 306, and 310 of the system 300 via the communication pathway 308. In one example, one or more of the devices 302/304 may receive such signals and, based on the received signals, determine an occurrence of an arrhythmia. In some cases, the device or devices 302/304 may communicate such determinations to one or more other devices 306 and 310 of the system 300. In some cases, one or more of the devices 302/304, 306, and 310 of the system 300 may take action based on the communicated determination of an arrhythmia, such as by delivering a suitable electrical stimulation to the heart of the patient. In another example, the LCPs 302 and/or 304 may sense indications of blood pressure (e.g., via one or more pressure sensors) and indications of volume (e.g., via an impedance between the electrodes of an LCP or between LCPs via an ultrasound transducer placed within the LCP, or via strain sensors placed on the heart in communication with the LCP). In one example, one or more of the devices 302/304 may receive such signals and, based on the received signals, determine a pressure-volume loop, and in some cases may communicate such information to one or more other devices 302/304, 306, and 310 of the system 300 via the communication pathway 308.

It is contemplated that the communication pathway 308 may communicate using RF signals, inductive coupling, conductive coupling optical signals, acoustic signals, or any other signals suitable for communication. Additionally, in at least some examples, the device communication pathway 308 may comprise multiple signal types. For instance, the other sensors/device 310 may communicate with the external device 306 using a first signal type (e.g., RF communication) but communicate with the LCPs 302/304 using a second signal type (e.g., conducted communication, inductive communication). Further, in some examples, communication between devices may be limited. For instance, as described above, in some examples, the LCPs 302/304 may communicate with the external device 306 only through the other sensors/devices 310, where the LCPs 302/304 send signals to the other sensors/devices 310, and the other sensors/devices 310 relay the received signals to the external device 306.

In some cases, the communication pathway 308 may include conducted communication. Accordingly, devices of the system 300 may have components that allow for such conducted communication. For instance, the devices of the system 300 may be configured to transmit conducted communication signals (e.g., current and/or voltage pulses) into the patient's body via one or more electrodes of a transmitting device, and may receive the conducted communication signals (e.g., pulses) via one or more electrodes of a receiving device. The patient's body may “conduct” the conducted communication signals (e.g., pulses) from the one or more electrodes of the transmitting device to the electrodes of the receiving device in the system 300. In such examples, the delivered conducted communication signals (e.g., pulses) may differ from pacing or other therapy signals. For example, the devices of the system 300 may deliver electrical communication pulses at an amplitude/pulse width that is sub-threshold to the heart. Although, in some cases, the amplitude/pulse width of the delivered electrical communication pulses may be above the capture threshold of the heart, but may be delivered during a refractory period of the heart and/or may be incorporated in or modulated onto a pacing pulse, if desired.

Delivered electrical communication pulses may be modulated in any suitable manner to encode communicated information. In some cases, the communication pulses may be pulse width modulated or amplitude modulated. Alternatively, or in addition, the time between pulses may be modulated to encode desired information. In some cases, conducted communication pulses may be voltage pulses, current pulses, biphasic voltage pulses, biphasic current pulses, or any other suitable electrical pulse as desired.

In some cases, the communication pathway 308 may include inductive communication, and when so provided, the devices of the system 300 may be configured to transmit/receive inductive communication signals.

FIGS. 4 and 5 show illustrative medical device systems that may be configured to operate according to techniques disclosed herein. In FIG. 4, an LCP 402 is shown fixed to the interior of the right ventricle of the heart 410, and a pulse generator 406 is shown coupled to a lead 412 having one or more electrodes 408a, 408b, 408c. In some cases, the pulse generator 406 may be part of a subcutaneous implantable cardioverter-defibrillator (S-ICD), and the one or more electrodes 408a, 408b, 408c may be positioned subcutaneously adjacent the heart. In some cases, the S-ICD lead may extend subcutaneously from the S-ICD can, around the sternum and one or more electrodes 408a, 408b, 408c may be positioned adjacent the interior surface of the sternum. In some cases, the LCP 402 may communicate with the subcutaneous implantable cardioverter-defibrillator (S-ICD).

In some cases, the LCP 402 may be in the left ventricle, right atrium or left atrium of the heart, as desired. In some cases, more than one LCP 402 may be implanted. For example, one LCP may be implanted in the right ventricle and another may be implanted in the right atrium. In another example, one LCP may be implanted in the right ventricle and another may be implanted in the left ventricle. In yet another example, one LCP may be implanted in each of the chambers of the heart.

In FIG. 5, an LCP 502 is shown fixed to the interior of the left ventricle of the heart 510, and a pulse generator 506 is shown coupled to a lead 512 having one or more electrodes 504a, 504b, 504c. In some cases, the pulse generator 506 may be part of an implantable cardiac pacemaker (ICP) and/or an implantable cardioverter-defibrillator (ICD), and the one or more electrodes 504a, 504b, 504c may be positioned in the heart 510. In some cases, the LCP 502 may communicate with the implantable cardiac pacemaker (ICP) and/or an implantable cardioverter-defibrillator (ICD).

The medical device systems 400 and 500 may also include an external support device, such as external support devices 420 and 520. The external support devices 420 and 520 can be used to perform functions such as device identification, device programming and/or transfer of real-time and/or stored data between devices using one or more of the communication techniques described herein. As one example, communication between the external support device 420 and the pulse generator 406 is performed via a wireless mode, and communication between the pulse generator 406 and the LCP 402 is performed via a conducted mode. In some examples, communication between the LCP 402 and the external support device 420 is accomplished by sending communication information through the pulse generator 406. However, in other examples, communication between the LCP 402 and the external support device 420 may be via a communication module. In some embodiments, the external support devices 420, 520 may be provided with or be in communication with a display 422, 522. The display 422, 522 may be a personal computer, tablet computer, smart phone, laptop computer, or other display as desired. In some instances, the display 422, 522 may include input means for receiving an input from a user. For example, the display 422, 522 may also include a keyboard, mouse, actuatable buttons, or be a touchscreen display. These are just examples.

FIGS. 4-5 illustrate two examples of medical device systems that may be configured to operate according to techniques disclosed herein. Other example medical device systems may include additional or different medical devices and/or configurations. For instance, other medical device systems that are suitable to operate according to techniques disclosed herein may include additional LCPs implanted within the heart. Another example medical device system may include a plurality of LCPs without other devices such as the pulse generator 406 or 506, with at least one LCP capable of delivering defibrillation therapy. In yet other examples, the configuration or placement of the medical devices, leads, and/or electrodes may be different from those depicted in FIGS. 4 and 5. Accordingly, it should be recognized that numerous other medical device systems, different from those depicted in FIGS. 4 and 5, may be operated in accordance with techniques disclosed herein. As such, the examples shown in FIGS. 4 and 5 should not be viewed as limiting in any way.

FIG. 6 is a side view of an illustrative implantable leadless cardiac pacemaker (LCP) 610. The LCP 610 may be similar in form and function to the LCP 100 described above. The LCP 610 may include any of the modules and/or structural features described herein. The LCP 610 may include a shell or housing 612 having a proximal end 614 and a distal end 616. The illustrative LCP 610 includes a first electrode 620 secured relative to the housing 612 and positioned adjacent to the distal end 616 of the housing 612 and a second electrode 622 secured relative to the housing 612 and positioned adjacent to the proximal end 614 of the housing 612. In some cases, the housing 612 may include a conductive material and may be insulated along a portion of its length. A section along the proximal end 614 may be free of insulation so as to define the second electrode 622. The electrodes 620, 622 may be sensing and/or pacing electrodes to provide electro-therapy and/or sensing capabilities. The first electrode 620 may be capable of being positioned against or may otherwise contact the cardiac tissue of the heart while the second electrode 622 may be spaced away from the first electrode 620. The first and/or second electrodes 620, 622 may be exposed to the environment outside the housing 612 (e.g., to blood and/or tissue).

It is contemplated that the housing 612 may take a variety of different shapes. For example, in some cases, the housing 612 may have a generally cylindrical shape. In other cases, the housing 612 may have a half-dome shape. In yet other embodiments, the housing 612 may be a rectangular prism. It is contemplated that the housing may take any cross sectional shape desired, including but not limited to annular, polygonal, oblong, square, etc.

In some cases, the LCP 610 may include a pulse generator (e.g., electrical circuitry) and a power source (e.g., a battery) within the housing 612 to provide electrical signals to the electrodes 620, 622 to control the pacing/sensing electrodes 620, 622. While not explicitly shown, the LCP 610 may also include a communications module, an electrical sensing module, a mechanical sensing module, and/or a processing module, and the associated circuitry, similar in form and function to the modules 102, 106, 108, 110 described above. The various modules and electrical circuitry may be disposed within the housing 612. Electrical communication between the pulse generator and the electrodes 620, 622 may provide electrical stimulation to heart tissue and/or sense a physiological condition.

In the example shown, the LCP 610 includes a fixation mechanism 624 proximate the distal end 616 of the housing 612. The fixation mechanism 624 is configured to attach the LCP 610 to a wall of the heart H, or otherwise anchor the LCP 610 to the anatomy of the patient. As shown in FIG. 6, in some instances, the fixation mechanism 624 may include one or more, or a plurality of hooks or tines 626 anchored into the cardiac tissue of the heart H to attach the LCP 610 to a tissue wall. In other instances, the fixation mechanism 624 may include one or more, or a plurality of passive tines, configured to entangle with trabeculae within the chamber of the heart H and/or a helical fixation anchor configured to be screwed into a tissue wall to anchor the LCP 610 to the heart H. These are just examples.

The LCP 610 may further include a docking member 630 proximate the proximal end 614 of the housing 612. The docking member 630 may be configured to facilitate delivery and/or retrieval of the LCP 610. For example, the docking member 630 may extend from the proximal end 614 of the housing 612 along a longitudinal axis of the housing 612. The docking member 630 may include a head portion 632 and a neck portion 634 extending between the housing 612 and the head portion 632. The head portion 632 may be an enlarged portion relative to the neck portion 634. For example, the head portion 632 may have a radial dimension from the longitudinal axis of the LCP 610 that is greater than a radial dimension of the neck portion 634 from the longitudinal axis of the LCP 610. In some cases, the docking member 630 may further include a tether retention structure (not explicitly shown) extending from or recessed within the head portion 632. The tether retention structure may define an opening configured to receive a tether or other anchoring mechanism therethrough. The retention structure may take any shape that provides an enclosed perimeter surrounding the opening such that a tether may be securably and releasably passed (e.g., looped) through the opening. In some cases, the retention structure may extend though the head portion 632, along the neck portion 634, and to or into the proximal end 614 of the housing 612. The docking member 630 may be configured to facilitate delivery of the LCP 610 to the intracardiac site and/or retrieval of the LCP 610 from the intracardiac site. While this describes one example docking member 630, it is contemplated that the docking member 630, when provided, can have any suitable configuration.

It is contemplated that the LCP 610 may include one or more pressure sensors 640 coupled to or formed within the housing 612 such that the pressure sensor(s) is exposed to and/or otherwise operationally coupled with the environment outside the housing 612 to measure blood pressures within the heart. In some cases, the one or more pressure sensors 640 may be coupled to an exterior surface of the housing 612. In other cases, the one or more pressures sensors 640 may be positioned within the housing 612 with a pressure acting on the housing and/or a port on the housing 612 to affect the pressure sensor 640. For example, if the LCP 610 is placed in the right ventricle, the pressure sensor(s) 640 may measure the pressure within the right ventricle. If the LCP 610 is placed in another portion of the heart (such as one of the atriums or the left ventricle), the pressures sensor(s) may measure the pressure within that portion of the heart. It is contemplated that the pressure sensor(s) 640 may be sensitive enough to detect a pressure change in the right atrium (e.g. atrial kick) when the LCP is placed in the right ventricle. Some illustrative pressure sensor configurations will be described in more detail herein.

In some instances, the pressure sensor(s) 640 may include a deformable diaphragm formed in part or in whole from a piezoelectric material which does not require external power to function. In some instances, the pressure sensor(s) 640 may include a MEMS device, such as a MEMS device with a pressure diaphragm with one or more piezoelectric sensors and/or piezoresistors on the diaphragm, a capacitor-Micro-machined Ultrasonic Transducer (cMUT), a condenser, a micromanometer, a surface acoustic wave (SAW) device, and/or any other suitable sensor adapted for measuring a pressure exerted on the diaphragm. Some illustrative but non-limiting pressure sensors and configurations are describe in commonly assigned Patent Application No. 62/413,766 entitled “IMPLANTABLE MEDICAL DEVICE WITH PRESSURE SENSOR and filed on Oct. 27, 2016, which is hereby incorporated by reference. It is contemplated that when piezoresistors are used, a piezo-resistive bridge may be operated in a low power mode (e.g., limited duty-cycle excitation) to reduce the power demand of the sensor. In some cases, the gain may be modulated to further reduce power demands.

When a piezoelectric material is used, the piezoelectric material may generate an electrical voltage (and/or electric current) between a first pressure sensor electrode and a second pressure sensor electrode in response to a pressure change applied to the piezoelectric material. The electrical voltage (and/or electric current) may be representative of the pressure change. In this instance, the piezoelectric material may not require any external power, but rather the piezoelectric material itself may convert energy extracted from the change in pressure into an electrical voltage (and/or electric current), which can then be used by the LCP to identify a pressure change. In some cases, it may not be necessary or even desirable to measure an absolute pressure value. Instead, just detecting a pressure change is all that is necessary to identify certain pressure events.

The pressures sensor(s) 640 may be part of a mechanical sensing module described herein. It is contemplated that the pressure measurements obtained from the pressures sensor(s) 640 may be used to generate a pressure curve over cardiac cycles. The pressure sensor(s) 640 may measure/sense pressure in the chamber in which the LCP 610 is implanted. For example, an LCP 610 implanted in the right ventricle (RV) could sense RV pressure. It is further contemplated that the pressure sensor(s) 640 may be sensitive enough to detect pressure changes in other chambers as well as the chamber in which the LCP 610 is positioned. For example, when the LCP 610 is positioned within the right ventricle, the pressure sensor(s) 640 may detect pressure changes in the right atrium (e.g. atrial kick) in addition to pressure changes in the right ventricle.

In some cases, sensing atrial pressure events may allow the device 610 to detect an atrial contraction, resulting in for example an atrial kick. Such a change in atrial pressure event may be used by an LCP in the right ventricle to time a pacing pulse for the ventricle in support of treating bradycardia events. In some cases, the timing of the ventricle pacing pulse may be adjusted to maximize the amount of blood entering the right ventricle through passive filling. In some instances, this may include adjusting an AV delay relative to the atrial fiducial (e.g. atrial kick). In some cases, a measured pressure change over time may be used to support management of a CRT cardiac therapy (if placed in the left ventricle), patient health status monitoring and/or any other suitable goal. It is contemplated measuring pressure events in both the ventricle and atrium using a single LCP may replicate a dual chamber system with a single device. For example, such a system may enable a device to be positioned in the ventricle while listening to both the ventricle and the atrium and pacing accordingly (e.g., a VDD device).

The pressure sensor(s) 640 may be configured (either alone or in combination with other circuitry in the LCP 610) to derive a change in pressure over time and may be used to adjust atrium to ventricle (AV) pacing delay to optimize pacing for treating bradycardia events. In some cases, the pressure sensor(s) 640 may be configured to detect a-waves (e.g. atrial kick) and change the pacing timing of the LCP 610 for ventricular pacing in relation to the contraction of the right atrium. It is further contemplated that sensing pressure could be used during the implant procedure to optimize the placement of the LCP 610 in the chamber (e.g., RV by sampling at different implant locations and using the best location). In some cases, frequent pressure monitoring may be beneficial for management of heart failure patients. Frequent pressure monitoring may also be useful for patients with chronic heart disease, hypertension, regurgitation, valve issues, atrial contraction detection, and to aid in addressing other problems. It is further contemplated that the pressure sensor(s) 640 may be used for monitoring respiration and associated diseases (e.g., chronic obstructive pulmonary disease (COPD), etc.). These are just examples.

In some cases, pressure readings may be taken in combination with a cardiac chamber volume measurement such an impedance measurement (e.g., the impedance between electrodes 620 and 622) to generate a pressure-impedance loop for one or more cardiac cycles. The impedance may be a surrogate for chamber volume, and thus the pressure-impedance loop may be representative of a pressure-volume loop for the heart H.

FIG. 7A is a plan view of the example leadless cardiac pacing device 610 implanted within a right ventricle RV of the heart H during ventricular filling. The right atrium RA, left ventricle LV, left atrium LA, and aorta A are also illustrated. FIG. 7B is a plan view of the leadless cardiac pacing device 610 implanted within a right ventricle of the heart H during ventricular contraction. These figures illustrate how the volume of the right ventricle may change over a cardiac cycle. As can be seen in FIGS. 7A and 7B, the volume of the right ventricle during ventricular filling is larger than the volume of the right ventricle of the heart during ventricular contraction.

In some cases, the processing module and/or other control circuitry may capture, at a time point within each of one or more cardiac cycles, one or more pressures within the heart (e.g., right ventricle and/or right atrium), resulting in one or more pressure data points. These one or more data points may be used, in combination with other pressure data points taken at different times during the one or more cardiac cycles, to generate a pressure curve. In some cases, one or more parameters may be extracted or derived from the pressure curve. The pressure curve may be used to facilitate cardiac resynchronization therapy (CRT), patient health status monitoring, and/or the management of a non-CRT cardiac therapy.

FIG. 8 is a graph 800 showing example pressures and volumes within a heart over time. More specifically, FIG. 8 depicts the aortic pressure, left ventricular pressure, left atrial pressure, left ventricular volume, an electrocardiogram (ECG or egram), and heart sounds of the heart H. A cardiac cycle may begin with diastole, and the mitral valve opens. The ventricular pressure falls below the atrial pressure, resulting in the ventricular filling with blood. During ventricular filling, the aortic pressure slowly decreases as shown. During systole, the ventricle contracts. When ventricular pressure exceeds the atrial pressure, the mitral valve closes, generating the S1 heart sound. Before the aortic valve opens, an isovolumetric contraction phase occurs where the ventricle pressure rapidly increases but the ventricular volume does not significantly change. Once the ventricular pressure equals the aortic pressure, the aortic valve opens and the ejection phase begins where blood is ejected from the left ventricle into the aorta. The ejection phase continues until the ventricular pressure falls below the aortic pressure, at which point the aortic valve closes, generating the S2 heart sound. At this point, the isovolumetric relaxation phase begins and ventricular pressure falls rapidly until it is exceeded by the atrial pressure, at which point the mitral valve opens and the cycle repeats. Contractions of the atria are initiated near the end of ventricular diastole. The active atrial contraction pushes or forces additional volumes of blood into the ventricles (often referred to as “atrial kick”) in addition to the volumes associated with passive filling. In some cases, the atrial kick contributes in the range of about 20% of the volume of blood toward ventricular preload. At normal heart rates, the atrial contractions are considered essential for adequate ventricular filling. However, as heart rates increase, atrial filling becomes increasingly important for ventricular filling because the time interval between contractions for passive filling becomes progressively shorter. Cardiac pressure curves for the pulmonary artery, the right atrium, and the right ventricle, and the cardiac volume curve for the right ventricle, similar to those illustrated in FIG. 8 for the left part of the heart, may be likewise generated. Typically, the cardiac pressure in the right ventricle is lower than the cardiac pressure in the left ventricle.

In one example, the heart sound signals can be recorded using acoustic sensors, (for example, a microphone), which capture the acoustic waves resulted from heart sounds. In another example, the heart sound signals can be recorded using accelerometers or pressure sensors that capture the accelerations or pressure waves caused by heart sounds. The heart sound signals can be recorded within or outside the heart. These are just examples.

FIG. 9 is a cross-section of an illustrative implantable leadless cardiac pacemaker (LCP) 900. The LCP 900 may be similar in form and function to the LCPs 100, 610 described above. The LCP 900 may include any of the modules and/or structural features described above with respect to the LCPs 100, 610. The LCP 900 may include a shell or housing 902 having a proximal end 904 and a distal end 906. In the example shown, the LCP 900 does not include a docking member. However, in some cases, a docking member may be provided, such as a cage, a head or other feature extending proximally from adjacent the side walls of the housing 902. The illustrative LCP 900 includes a first electrode 908 secured relative to the housing 902 and positioned adjacent to the distal end 906 of the housing 902, and a second electrode (not explicitly shown) secured relative to the housing 902 and positioned adjacent to the proximal end 904 of the housing 902. In some instances, the first electrode 908 may be positioned on a distal end surface facing distally. In some cases, the housing 902 may include a conductive material and may be insulated along a portion of its length. A section along the proximal end 904 may be free of insulation so as to define the second electrode. The electrodes 908 may be sensing and/or pacing electrodes to aid in providing electro-therapy and/or sensing capabilities. The first electrode 908 may be capable of being positioned against or may otherwise contact the cardiac tissue of the heart while the second electrode may be spaced away from the first electrode 908. The first and/or second electrodes 908 may be exposed to the environment outside the housing 902 (e.g., to blood and/or tissue).

In some cases, the LCP 900 may include a pulse generator (e.g., electrical circuitry) 910 and a power source (e.g., a battery) 912 within the housing 902 to provide and/or receive electrical signals via the first and second electrodes. While not explicitly shown in FIG. 9, the LCP 900 may also include a communications module, an electrical sensing module, a mechanical sensing module, and/or a processing module, and associated circuitry, similar in form and function to the modules 102, 106, 108, 110 described above. The various modules and electrical circuitry may be disposed within the housing 902. Electrical communication between the pulse generator and the electrodes may provide electrical stimulation to heart tissue and/or sense a physiological condition.

In the example shown, the LCP 900 further includes a fixation mechanism 914 proximate the distal end 906 of the housing 902. The fixation mechanism 914 is configured to attach the LCP 900 to a wall of the heart H, or otherwise anchor the LCP 900 to the anatomy of the patient. As shown in FIG. 9, in some instances, the fixation mechanism 914 may include one or more, or a plurality of hooks or tines 916 anchored into the cardiac tissue of the heart H to attach the LCP 900 to a tissue wall. In other instances, the fixation mechanism 914 may include one or more, or a plurality of passive tines, configured to entangle with trabeculae within the chamber of the heart H and/or a helical fixation anchor configured to be screwed into a tissue wall to anchor the LCP 900 to the heart H. These are just examples.

The housing 902 may include a proximal end surface 918 facing proximally (e.g., in a generally opposite direction from the distal end surface. In some instances, the proximal end surface 918 of the housing 902 may form a diaphragm 920. In some cases, the diaphragm 920 may be formed from the housing material itself. When so provided, the wall thickness of the housing in the region of the diaphragm 920 may be thinned to increase the flexibility of the diaphragm 920 to as to be responsive (e.g. sufficiently deformable) to a pressure range of interest. In other cases, the diaphragm 920 may be formed from another material, such as but not limited to titanium, titanium foil, silicone, polyimides, etc. to form a deformable or movable diaphragm 920 that is responsive to a pressure of interest applied to the diaphragm 920. In some instances, the diaphragm 920 may be titanium or titanium foil on polyvinylidene fluoride (PVDF). In some instances, the diaphragm 920 may be formed from a piezoelectric material and/or may include a piezoelectric layer.

A piezoelectric material may exhibit the piezoelectric effect, or the ability to generate a voltage (and/or current) when the material is subjected to a mechanical stress or vibration. Some illustrative piezoelectric materials may include, but are not limited to some naturally occurring crystals (e.g., quartz, sucrose, Rochelle salt, topaz, lead titanate, etc.), synthetic crystals, ceramics (e.g., barium titanate, lead zirconate titanate (PZT), zinc oxide, etc.), polymers (e.g., polyvinylidene fluoride (PVDF)), etc. This list is not intended to be exhaustive of all types of piezoelectric materials, but rather illustrative of some example materials. When used as part of the hermetic seal around the LCP, it is contemplated that the material (piezoelectric or otherwise) selected for the diaphragm 920 may be hermetic. For example, the material should be capable of preventing blood from diffusing through the diaphragm and into the interior or the LCP.

In any event, the diaphragm 920 may be fabricated to flex or deform as the pressure (external to the housing 902) in the heart (e.g., right ventricle and/or right atrium) changes, as will be described in more detail herein. While the entire proximal end surface 918 may form the diaphragm 920, it is contemplated that only a portion of the end surface 918 may form the diaphragm 920. In some cases, the diaphragm 920 may be 1 millimeter in diameter or less. In other cases, the diaphragm 920 may be greater than 1 millimeter in diameter. In some cases, the diaphragm 920 may have a round shape. In other cases, the diaphragm 920 may have a square, rectangular or any other suitable shape. In some cases, the diaphragm 920 may not have a uniform thickness. In some cases, the diaphragm 920 may have thicker bossed regions that provide support to, for example, increase the linearity of the deformation of the diaphragm 920 with pressure.

In some cases, the diaphragm 920 may be formed from a piezoelectric material. As the diaphragm flexes or deforms in response to an external pressure, a voltage (and/or current) may be generated by the piezoelectric material between sensor electrodes on opposing sides of the piezoelectric material. The generated voltage (and/or current) may be transferred via one or more electrical conductors 924 to the electrical circuitry 910, which may identify a pressure event and/or pressure value. In some cases, the generated voltage (and/or current) may reflect a change in pressure over time as opposed to an absolute or gauge pressure. When so provided, a reference pressure may not be required. In any event, the change in pressure over time may be sufficient to identify events such as the atrial contraction (e.g., atrial kick), ventricular filling, ventricular ejection, etc. In some instances, the electrical circuitry 910 may be configured to obtain pressure measurements at a sample rate of greater than 100 Hertz (Hz), but this is not required. This may allow for pressure measurements to be used to determine characteristics of the cardiac cycle including, but not limited to, dP/dT, dicrotic notch, etc.

In some cases, the one or more electrical conductors 924 may include a first electrical conductor coupled to a first electrode on a first side of the piezoelectric material, and a second electrical conductor coupled a second electrode on a second opposite side of the piezoelectric material, such that the voltage (and/or current) generated is transmitted to the electrical circuitry 910.

The diaphragm 920 need not be placed on the proximal end surface 918 of the housing 902 such as shown in FIG. 9. It is contemplated that the diaphragm 920 may be formed in any surface that is exposed to the environment outside of the housing 902. In some cases, locating the diaphragm 920 on or adjacent to the proximal end 904 of the housing 902 may orientate the diaphragm towards the heart valves (when the LCP 900 is positioned in the apex of the heart) and in-line with expected maximum pressure changes within the heart, which may achieve higher signal-to-noise (SN) levels. This may also locate the diaphragm 920 away from the heart wall, which may reduce the likelihood that the diaphragm 920 will become fibrossed-over. In some cases, the diaphragm 920 may be coated with an anti-thrombogenic coating to help prevent tissue growth on or over the diaphragm 920.

In the example of FIG. 9, a battery 912 is shown adjacent the diaphragm 920. However, many different configurations of the internal components of the LCP 900 are contemplated. In the example shown, the processing module (e.g., circuitry or control electronics) 910 is positioned in a distal portion 906 of the housing 902 adjacent to the distal electrode. The one or more electrical conductors 924 may be formed of a polyimide or similar interconnect having a cross-sectional dimension in the range of less than 250 microns. It is contemplated that the inside surface of the housing 902 may be electrically insulated and the electrical conductors 924 (e.g., trace) may be positioned on the inside surface of the housing 902 or along the outer surface of the battery 912, as desired. Alternatively, wires or a ribbon cable may be used. These are just examples.

In some cases, the electrical circuitry 910 may be configured to obtain pressure measurements at predetermined intervals over one or more cardiac cycles. In other instances, the electrical circuitry 910 may be configured to obtain a pressure measurement in response to a specific cardiac event or at a specific time in a cardiac cycle. For example, the circuitry 910 may be configured to use one or more cardiac signals sensed by the first electrode 908 and/or second electrode to determine when the patient's heart is in a first phase of a cardiac cycle. The circuitry 910 may be configured to determine a pressure exterior to the housing 902 based at least in part on the pressure obtained during the first phase of the cardiac cycle. In some cases, the first phase may be systole and in other cases the first phase may be diastole. The circuitry 910 may also be configured to determine a pressure exterior to the housing 902 based at least in part on the pressure taken during a second phase of the cardiac cycle. It is contemplated that the circuitry 910 may be further configured to detect heart sounds of the patient's heart based at least in part on the pressure sensor output signal. For example, the first heart sound may be a timing fiducial for a sudden increase in pressure while the second heart sound may be a timing fiducial for a sudden decrease in pressure.

In some cases, the circuitry 910 of the LCP 900 may be configured to obtain a plurality of pressure readings over one or more cardiac cycles. The pressure readings may be plotted (either by the circuitry 910 or an external device) to form a graph similar to the one shown in FIG. 8. Various parameters related to the function of the heart can be extrapolated from the graph including but not limited to peak to peak measurements, dP/dT, time averaged values, inotropic response of the ventricle, etc. In some instances, the pressure measurements may be compared to calibration values (e.g., measurements taken at the time of implantation of the LCP 900). It is further contemplated that the diaphragm 920 may be sensitive enough to generate a voltage in response to a pressure increase in a chamber different from the chamber in which the LCP 900 is implanted. For example, when the LCP 900 is implanted in the right ventricle, the diaphragm may generate a voltage in response to a pressure increase in the right atrium (e.g. atrial kick) as well as a pressure increase in the right ventricle.

In some cases, the diaphragm 920 may be formed of the same material and of the same thickness as the remaining portion of the housing 902. For example, the housing 902 may flex or deform to transfer a pressure external to the housing 902 to a layer of piezoelectric material located within the housing 612. For example, the housing 902 may have a compliance such that the relative movement of the housing 902 in response to the external pressure may be operatively coupled to a piezoelectric material. The resulting voltage (and/or current) generated by the piezoelectric material may be calibrated relative to external pressures prior to implantation of the LCP 900 in a patient. The calibration data may be stored in the memory and/or electrical circuitry of the LCP 900. In some cases, there may be some pressure loss (e.g., in the range of 1-20% or more) between the pressure exerted on the housing 902 and the pressure applied to the piezoelectric material, depending on the placement of the piezoelectric material. This pressure loss may be compensated for (e.g., nullified) by adjusting the algorithm that converts the voltage (and/or current) generated by the piezoelectric material to a pressure using the calibration data stored in the LCP 900.

FIG. 10 illustrates a proximal end portion 954 of another illustrative LCP 950 having a diaphragm 960 and a piezoelectric membrane 962. The LCP 950 may be similar in form and function to the LCPs 100, 610, 900 described above. The LCP 950 may include any of the modules and/or structural features described above with respect to the LCPs 100, 610, 900.

The illustrative LCP 950 may include a shell or housing 952 having a proximal end portion 954 and a distal end (not explicitly shown). The housing 952 may include a proximal end surface 956 facing proximally (e.g., in a generally opposite direction from the distal end surface). In some instances, the proximal end surface 956 of the housing 952 may form a diaphragm 960. In some cases, the diaphragm 960 may be formed from the housing material itself, but this is not required. When so provided, the wall thickness of the housing in the region of the diaphragm 960 may be thinned to increase the flexibility of the diaphragm 960, although this is not required. In some cases, the diaphragm 960 may be formed from another material, such as but not limited to titanium, titanium foil, silicone, polyimides, etc. to form a deformable or movable diaphragm 960 that is responsive to a desired pressure range applied to the diaphragm 960.

In the example shown, the diaphragm 960 may flex or deform and transfer a pressure applied from external to the housing 952 to a layer of piezoelectric material 962 located within the housing 952. For example, the housing 952 may have a compliance such that the relative movement of the housing 952 and/or diaphragm 960 in response to the external pressure may deform or otherwise apply a corresponding stress to a piezoelectric material or membrane 962. In some embodiments, the piezoelectric membrane 962 may be coupled to or positioned on an interior surface of the diaphragm 960, although this is not required.

As the diaphragm 960 flexes in response an external pressure, the piezoelectric membrane 962 may also flex. The applied stress to the piezoelectric membrane 962 may generate a voltage (and/or a current) between a first sensor electrode on one side of the piezoelectric membrane 962 and a second sensor electrode on the opposing side of the piezoelectric membrane 962. The voltage (and/or current) may be transferred via one or more electrical conductors 964 to the electrical circuitry of the LCP 950 where it may be converted from a voltage (and/or current) to a pressure reading. In some cases, the one or more electrical conductors 964 may include a first electrical conductor coupled to a first side of the piezoelectric membrane 962 and a second electrical conductor coupled a second side, opposite of the first side such that the voltage (and/or current) generated is transmitted to the electrical circuitry. In some instances, the electrical conductors may be coupled to the first and second sensor electrodes generally shown at 968.

The voltage (and/or current) generated by the piezoelectric material may be calibrated relative to external pressures applied prior to implantation of the LCP 950 in a patient. The calibration data may be stored in the memory and/or electrical circuitry of the LCP 950. In some cases, there may be some pressure loss (e.g., in the range of 1-20% or more) between the pressure exerted on the housing 952 and the pressure applied to the piezoelectric membrane 962. This pressure loss may be compensated for (e.g., nullified) by adjusting the algorithm that converts the voltage (and/or current) generated by the piezoelectric membrane 962 to a pressure using the calibration data stored in the LCP 950.

In the example of FIG. 10, the battery 966 is shown adjacent the diaphragm 960. However, many different configurations of the internal components of the LCP 950 are contemplated. In the example shown, the processing module (e.g., circuitry or control electronics) may be positioned in a distal portion of the housing 952 adjacent to the distal electrode. The one or more electrical conductors 964 may be formed of a polyimide or similar interconnect having a cross-sectional dimension in the range of less than 250 microns. It is contemplated that the inside surface of the housing 952 may be electrically insulated and the electrical conductors 964 (e.g., trace) may be positioned on the inside surface of the housing 952 or along the outer surface of the battery 966, as desired. Alternatively, wires or a ribbon cable may be used. These are just examples.

FIG. 11 illustrates a proximal end portion 1004 of another illustrative LCP 1000 having a diaphragm 1006 and a piezoelectric membrane 1010. The LCP 1000 may be similar in form and function to the LCPs 100, 610, 900 described above. The LCP 1000 may include any of the modules and/or structural features described above with respect to the LCPs 100, 610, 900.

The illustrative LCP 1000 may include a shell or housing 1002 having a proximal end portion 1004 and a distal end (not explicitly shown). The housing 1002 may include a proximal end surface 1018 facing proximally (e.g., in a generally opposite direction from the distal end surface). In some instances, the proximal end surface 1018 of the housing 1002 may form a diaphragm 1006. In some cases, the diaphragm 1006 may be formed from the housing material itself, although this is not required. When so provided, the wall thickness of the housing in the region of the diaphragm 1006 may be thinned to increase the flexibility of the diaphragm 1006, although this is not required. In some cases, the diaphragm 1006 may be formed from another material, such as but not limited to titanium, titanium foil, silicone, polyimides, etc. to form a deformable or movable diaphragm 1006 that is responsive to a desired pressure range applied to the diaphragm 1006.

The diaphragm 1006 may flex or deform to transfer a pressure external to the housing 1002 to a layer of piezoelectric material or a piezoelectric membrane 1010 located within the housing 1002. For example, the housing 1002 may have a compliance such that the relative movement of the housing 1002 and/or diaphragm 1006 in response to the external pressure may be mechanically coupled to a piezoelectric material or membrane 1010. In some embodiments, the piezoelectric membrane 1010 may be coupled to the diaphragm 1006 via a mechanical linkage or arm 1008. This may allow the piezoelectric membrane 1010 to be spaced a distance from the housing 1002 while still flexing in response to an externally applied pressure 1016. In some cases, it may be desirable for a more rigid piezoelectric material to be used, and the mechanical leverage provide by the mechanical linkage or arm 1008 may allow a more modest external pressure applied to the diaphragm 1006 to suitable stress the piezoelectric membrane 1010 to produce a desired voltage (and/or current). In the example shown, as the diaphragm 1006 flexes in response the external pressure 1016, the linkage 1008 also moves and transfers the force to the piezoelectric membrane 1010. The force applied to the piezoelectric membrane 1010 generates an voltage (and/or a current), which may be transferred via one or more electrical conductors 1012 to the electrical circuitry of the LCP 1000 where it is converted from an voltage (and/or current) to a pressure reading. In some cases, the one or more electrical conductors 1012 may include a first electrical conductor coupled to a first side of the piezoelectric membrane 1010 and a second electrical conductor coupled a second side, opposite of the first side of the piezoelectric membrane 1010, such that the voltage (and/or current) generated across the piezoelectric membrane 1010 is transmitted to the electrical circuitry. In some instances, the electrical conductors may be coupled to first and second pressure sensor electrodes positioned on opposite sides of the piezoelectric membrane 1010.

The voltage generated by the piezoelectric membrane 1010 may be calibrated relative to external pressures prior to implantation of the LCP 1000 in a patient. The calibration data may be stored in the memory and/or electrical circuitry of the LCP 1000. In some cases, there may be some pressure loss (e.g., in the range of 1-20% or more) between the pressure exerted on the housing 1002 and the pressure applied to the piezoelectric membrane 1010, depending on the linkage or arm 1008. This pressure loss may be compensated for (e.g., nullified) by adjusting the algorithm that converts the voltage (and/or current) generated by the piezoelectric material to a pressure using the calibration data stored in the LCP 1000.

In the example shown in FIG. 11, the battery 1014 is shown adjacent the piezoelectric membrane 1010. However, many different configurations of the internal components of the LCP 1000 are contemplated. In the example shown, the processing module (e.g., circuitry or control electronics) may be positioned in a distal portion of the housing 1002 adjacent to the distal electrode. The one or more electrical conductors 1012 may be formed of a polyimide or similar interconnect having a cross-sectional dimension in the range of less than 250 microns. It is contemplated that the inside surface of the housing 1002 may be electrically insulated and the electrical conductors 1012 (e.g., trace) may be positioned on the inside surface of the housing 1002 or along the outer surface of the battery 1014, as desired. Alternatively, wires or a ribbon cable may be used. These are just examples.

FIG. 12 illustrates a proximal end portion 1054 of another illustrative LCP 1050 having a diaphragm 1056 and a piezoelectric membrane 1062. The illustrative LCP 1050 may be similar in form and function to the LCPs 100, 610, 900 described above. The LCP 1050 may include any of the modules and/or structural features described above with respect to the LCPs 100, 610, 900.

The illustrative LCP 1050 may include a shell or housing 1052 having a proximal end portion 1054 and a distal end (not explicitly shown). The housing 1052 may include a proximal end surface 1066 facing proximally (e.g., in a generally opposite direction from the distal end surface). In some instances, the proximal end surface 1066 of the housing 1052 may form a diaphragm 1056. In some cases, the diaphragm 1056 may be formed from the housing material itself, but this is not required. When so provided, the wall thickness of the housing in the region of the diaphragm 1056 may be thinned to increase the flexibility of the diaphragm 1056, although this is not required. In other cases, the diaphragm 1056 may be formed from another material, such as but not limited to titanium, titanium foil, silicone, polyimides, etc. to form a deformable or movable diaphragm 1056 that is responsive to a desired pressure range applied to the diaphragm 1056.

The diaphragm 1056 may flex or deform to transfer a pressure external to the housing 1052 to a layer of piezoelectric material or a piezoelectric membrane 1062 located within the housing 1052. In the example shown, a cavity 1064 filled with a fluid 1068 may be positioned between the external diaphragm 1056 and an internal diaphragm 1058. The fluid filled cavity 1064 may be in fluid communication with the diaphragm(s) 1056, 1058 such that the fluid filled cavity 1064 may communicate a measure related to the pressure 1070 applied by the environment to the diaphragm 1056 of the housing 1052 ultimately to piezoelectric membrane 1062. The fluid filled cavity 1064 may be filled with an incompressible fluid 1068. In some cases, the fluid filled cavity 1064 may be filled with a non-conductive fluid 1068. In some cases, the fluid 1068 may be highly soluble to gases that may arise inside of the housing, particularly at body temperature (e.g., 37° C.). For example, the fluid 1068 may be highly soluble to hydrogen, helium, nitrogen, argon, water, and/or other gases or liquids that might arise inside of the housing as a result of, for example, outgassing of internal components of the LCP 1050.

The diaphragms 1056, 1058 may have a compliance such that the relative movement of the housing 1052 and/or diaphragm 1056 in response to the external pressure may be coupled to the piezoelectric material or membrane 1062, sometimes through a mechanical linkage or arm 1060. In FIG. 12, the piezoelectric membrane 1062 is shown mechanically coupled to the inner diaphragm 1058 via a mechanical linkage or arm 1060. However, it is contemplated that the piezoelectric material or membrane 1062 may be adhered directly to the inner diaphragm 1058, or the inner diaphragm 1058 may be made from or otherwise form the piezoelectric material or membrane 1062.

As the diaphragm 1056 flexes in response the external pressure 1070, force is transferred 1072 through the fluid filled cavity 1064 to the inner diaphragm 1058. The inner diaphragm 1058 then transfers the force to the piezoelectric material or membrane 1062, sometimes through a mechanical linkage or arm 1060. The force applied to the piezoelectric membrane 1062 generates an voltage (and/or s current). The voltage (and/or current) may be transferred via one or more electrical conductors 1074 to the electrical circuitry of the LCP 1050 where it is converted from a voltage (and/or a current) to a pressure reading.

In some cases, the one or more electrical conductors 1024 may include a first electrical conductor coupled to a first side of the piezoelectric membrane 1062 and a second electrical conductor coupled a second side, opposite of the first side of the piezoelectric membrane 1062, such that the voltage (and/or current) generated across the piezoelectric membrane 1062 is transmitted to the electrical circuitry. In some instances, the electrical conductors may be coupled to first and second pressure sensor electrodes positioned on opposite sides of the piezoelectric membrane 1062.

The voltage generated by the piezoelectric material may be calibrated relative to external pressures applied prior to implantation of the LCP 1050 in a patient. The calibration data may be stored in the memory and/or electrical circuitry of the LCP 1050. In some cases, there may be some pressure loss (e.g., in the range of 1-20% or more) between the pressure exerted on the housing 1052 and the pressure applied to the piezoelectric membrane 1062. This pressure loss may be compensated for (e.g., nullified) by adjusting the algorithm that converts the voltage (and/or current) generated by the piezoelectric material to a pressure using the calibration data stored in the LCP 1050.

In the example of FIG. 12, the battery 1076 is shown adjacent the piezoelectric membrane 1062. However, many different configurations of the internal components of the LCP 1050 are contemplated. In the example shown, the processing module (e.g., circuitry or control electronics) may be positioned in a distal portion of the housing 1052 adjacent to the distal electrode. The one or more electrical conductors 1074 may be formed of a polyimide or similar interconnect having a cross-sectional dimension in the range of less than 250 microns. It is contemplated that the inside surface of the housing 1052 may be electrically insulated and the electrical conductors 1074 (e.g., trace) may be positioned on the inside surface of the housing 1052 or along the outer surface of the battery 1076, as desired. Alternatively, wires or a ribbon cable may be used. These are just examples.

FIG. 13 illustrates a proximal end portion 1104 of another illustrative LCP 1100 having a diaphragm 1106 and a piezoelectric membrane 1108. The LCP 1100 may be similar in form and function to the LCPs 100, 610, 900 described above. The LCP 1100 may include any of the modules and/or structural features described above with respect to the LCPs 100, 610, 900.

The LCP 1100 may include a shell or housing 1102 having a proximal end portion 1104 and a distal end (not explicitly shown). The housing 1102 may include a proximal end surface 1110 facing proximally (e.g., in a generally opposite direction from the distal end surface). In some instances, the proximal end surface 1110 of the housing 1102 may form a diaphragm 1106. In some cases, the diaphragm 1106 may be formed from the housing material itself, but this is not required. When so provided, the wall thickness of the housing in the region of the diaphragm 1106 may be thinned to increase the flexibility of the diaphragm 1106, although this is not required. In some cases, the diaphragm 1106 may be formed from another material, such as but not limited to titanium, titanium foil, silicone, polyimides, etc. to form a deformable or movable diaphragm 1106 that is responsive to a desired pressure range applied to the diaphragm 1106.

The diaphragm 1106 may flex or deform to transfer a pressure external to the housing 1102 to a layer of piezoelectric material or a piezoelectric membrane 1108 located within the housing 1102. In some embodiments, a cavity 1112 filled with a fluid 1114 may be positioned between the diaphragm 1106 and the piezoelectric membrane 1108. The fluid filled cavity 1112 is shown in fluid communication with the diaphragm 1106 such that the fluid filled cavity 1112 may communicate a measure related to the pressure 1116 applied by the environment to the piezoelectric membrane 1108. The fluid filled cavity 1112 may be filled with an incompressible fluid 1114. In some cases, the fluid filled cavity 1112 may be filled with a non-conductive fluid 1114. In some cases, the fluid 1114 may be highly soluble to gases that may be inside of the housing, particularly at body temperature (e.g., 37° C.). For example, the fluid 1114 may be highly soluble to hydrogen, helium, nitrogen, argon, water, and/or other gases or liquids that might arise inside of the housing as a result of, for example, outgassing of internal components of the LCP 1100.

The diaphragm 1106 may have a compliance such that the relative movement of the housing 1102 and/or diaphragm 1106 in response to a desired range of external pressures is coupled 1118 to the piezoelectric material or membrane 1108 though the fluid 1114. The force 1118 applied to the piezoelectric membrane 1108 may generate a voltage (and/or a current). The voltage (and/or current) may be transferred via one or more electrical conductors 1120 to the electrical circuitry of the LCP 1100 where it may be converted from a voltage (and/or current) to a pressure reading. It is contemplated that in some instances, the piezoelectric membrane 1108 may be formed from a piezoelectric material or have a piezoelectric material formed on a surface of another flexible material as described with respect to, for example, FIG. 10.

In some cases, the one or more electrical conductors 1120 may include a first electrical conductor coupled to a first side of the piezoelectric membrane 1108 and a second electrical conductor coupled a second side, opposite of the first side of the piezoelectric membrane 1108, such that the voltage (and/or current) generated by the piezoelectric material or membrane 1108 is transmitted to the electrical circuitry. In some instances, the electrical conductors may be coupled to first and second pressure sensor electrodes positioned on opposite sides of the piezoelectric membrane 1108.

The voltage (and/or current) generated by piezoelectric membrane 1108 may be calibrated relative to external pressures applied prior to implantation of the LCP 1100 in a patient. The calibration data may be stored in the memory and/or electrical circuitry of the LCP 1100. In some cases, there may be some pressure loss (e.g., in the range of 1-20% or more) between the pressure exerted on the housing 1102 and the pressure applied to the piezoelectric membrane 1108. This pressure loss may be compensated for (e.g., nullified) by adjusting the algorithm that converts the voltage (and/or current) generated by the piezoelectric membrane 1108 to a pressure using the calibration data stored in the LCP 1100.

In the example of FIG. 13, the battery 1122 is shown adjacent the piezoelectric membrane 1108. However, many different configurations of the internal components of the LCP 1100 are contemplated. In the example shown, the processing module (e.g., circuitry or control electronics) may be positioned in a distal portion of the housing 1102 adjacent to the distal electrode. The one or more electrical conductors 1120 may be formed of a polyimide or similar interconnect having a cross-sectional dimension in the range of less than 250 microns. It is contemplated that the inside surface of the housing 1102 may be electrically insulated and the electrical conductors 1120 (e.g., trace) may be positioned on the inside surface of the housing 1102 or along the outer surface of the battery 1122, as desired. Alternatively, wires or a ribbon cable may be used. These are just examples.

FIG. 14 illustrates a cross-sectional view of a proximal end portion 1154 of another illustrative LCP 1150 having a diaphragm 1156 and piezoelectric membrane 1158. The LCP 1150 may be similar in form and function to the LCPs 100, 610, 900 described above. The LCP 1150 may include any of the modules and/or structural features described above with respect to the LCPs 100, 610, 900.

The LCP 1150 may include a shell or housing 1152 having a proximal end portion 1154 and a distal end (not explicitly shown). In this example, the housing 1152 includes a docking member 1160 extending proximally from the proximal end portion 1154. The docking member 1160 may be configured to facilitate delivery and/or retrieval of the LCP 1150. For example, the docking member 1160 may extend from the proximal end portion 1154 of the housing 1152 along a longitudinal axis of the housing 1152. The docking member 1160 may include a head portion 1162 and a neck portion 1164 extending between the housing 1152 and the head portion 1162. The head portion 1162 may be an enlarged portion relative to the neck portion 1164. An access port 1166 may extend through the head portion 1162 and the neck portion 1164 to fluidly couple the diaphragm 1156 with the blood in the heart. The diaphragm 1156 may be constructed using any of the materials and/or configurations described herein. In some cases, the diaphragm 1156 may be positioned at the proximal opening 1168 of the access port 1166.

It is contemplated that the docking member 1160 may be formed as a separate structure from the housing 1152 and subsequently attached to the housing 1152. For example, the docking member 1160 may be 3-D metal structure that is welded (or otherwise coupled or secured) to the housing 1152. In other embodiments, the docking member 1160 and the housing 1152 may be formed as a single monolithic structure.

A piezoelectric membrane 1158 may be positioned adjacent to, but not necessarily in direct contact with the diaphragm 1156. In some cases, the piezoelectric membrane 1158 may be positioned directly on an inner surface of the diaphragm 1156, such as described with respect to FIG. 10. In other embodiments, the piezoelectric membrane 1158 may be mechanically and/or fluidly coupled to the diaphragm 1156 through a mechanical linkage and/or a fluid filled chamber, similar to that described above. As the diaphragm 1156 flexes in response the an external pressure, the piezoelectric membrane 1158 may also flex. The stress on the piezoelectric membrane 1158 may generate a voltage (and/or current). The voltage (and/or current) may be transferred via one or more electrical conductors 1170 to the electrical circuitry of the LCP 1150 where it is converted from a voltage (and/or current) to a pressure reading. In some embodiments, the piezoelectric membrane 1158 may be operatively connected to the housing 1152 which in turn is operatively coupled to the circuitry or control electronics.

In some cases, the one or more electrical conductors 1170 may include a first electrical conductor coupled to a first side of the piezoelectric membrane 1158 and a second electrical conductor coupled a second side, opposite of the first side of the piezoelectric membrane 1158, such that the voltage (and/or current) generated across the piezoelectric membrane 1158 is transmitted to the electrical circuitry. In some instances, the electrical conductors may be coupled to first and second pressure sensor electrodes positioned on opposite sides of the piezoelectric membrane 1158.

FIG. 14 illustrates the battery 1172 adjacent to the piezoelectric membrane 1158. However, many different configurations of the internal components of the LCP 1150 are contemplated. The one or more electrical conductors 1170 may be formed of a polyimide or similar interconnect having a cross-sectional dimension in the range of less than 250 microns. It is contemplated that the inside surface of the housing 1152 may be electrically insulated and the electrical conductors 1170 (e.g., trace) positioned on the inside surface of the housing 1152 or along the outer surface of the battery 1172, as desired. Alternatively, wires or a ribbon cable may be used. These are just examples.

FIG. 15 illustrates a cross-sectional view of a proximal end portion 1204 of another illustrative LCP 1200 having a diaphragm 1206 and a piezoelectric membrane 1208. The LCP 1200 may be similar in form and function to the LCPs 100, 610, 900 described above. The LCP 1200 may include any of the modules and/or structural features described above with respect to the LCPs 100, 610, 900.

The LCP 1200 may include a shell or housing 1202 having a proximal end portion 1204 and a distal end (not explicitly shown). The housing 1202 may include a docking member 1210 extending proximally from the proximal end portion 1204. The docking member 1210 may be configured to facilitate delivery and/or retrieval of the LCP 1200. For example, the docking member 1210 may extend from the proximal end portion 1204 of the housing 1202 along a longitudinal axis of the housing 1202. The docking member 1210 may include a head portion 1212 and a neck portion 1214 extending between the housing 1202 and the head portion 1212. The head portion 1212 may be an enlarged portion relative to the neck portion 1214. An access port 1216 may extend through the head portion 1212 and the neck portion 1214 to fluidly couple the diaphragm 1206 with the blood in the heart. The diaphragm 1206 may be constructed using any of the materials and/or configurations described herein. In some cases, the diaphragm 1206 may be positioned at the proximal opening 1168 of the access port 1216.

It is contemplated that the docking member 1210 may be formed as a separate structure from the housing 1202 and subsequently attached to the housing 1202. For example, the docking member 1210 may be 3-D metal structure that is welded (or otherwise coupled or secured) to the housing 1202. In other embodiments, the docking member 1210 and the housing 1202 may be formed as a single monolithic structure.

A piezoelectric membrane 1208 may be positioned adjacent to, but not necessarily in direct contact with the diaphragm 1206. In some embodiments, the piezoelectric membrane 1208 may be coupled to the diaphragm 1206 via a mechanical linkage or arm 1218. At least part of the piezoelectric membrane 1208 may be held in place relative to the housing 1202 such that movement of the diaphragm 1206 and mechanical linkage or arm 1218 relative to the piezoelectric membrane 1208 induces a stress in the piezoelectric membrane 1208. As the diaphragm 1206 flexes in response the external pressure 1220, the linkage 1218 moves and transfers the force to the piezoelectric membrane 1208. The force applied to the piezoelectric membrane 1208 generates a voltage (and/or current). The voltage (and/or current) may be transferred via one or more electrical conductors 1222 to the electrical circuitry of the LCP 1000 where it is converted from a voltage (and/or current) to a pressure reading.

In some cases, the one or more electrical conductors 1222 may include a first electrical conductor coupled to a first side of the piezoelectric membrane 1208 and a second electrical conductor coupled a second opposite side of the piezoelectric membrane 1208 such that the voltage (and/or current) generated across the piezoelectric membrane 1208 is transmitted to the electrical circuitry. In some instances, the electrical conductors may be coupled to first and second pressure sensor electrodes positioned on opposite sides of the piezoelectric membrane 1208.

FIG. 15 illustrates the battery 1224 adjacent to the piezoelectric membrane 1208. However, many different configurations of the internal components of the LCP 1200 are contemplated. The one or more electrical conductors 1222 may be formed of a polyimide or similar interconnect having a cross-sectional dimension in the range of less than 250 microns. It is contemplated that the inside surface of the housing 1202 may be electrically insulated and the electrical conductors 1222 (e.g., trace) positioned on the inside surface of the housing 1202 or along the outer surface of the battery 1224, as desired. Alternatively, wires or a ribbon cable may be used. These are just examples.

It is contemplated that any of the embodiments described herein may be modified to include a plurality (e.g., two or more) diaphragms and/or piezoelectric membranes to improve the sensitivity of the pressure readings. For example, it may be desirable for the diaphragm(s) to have the largest surface area possible. This may be accomplished through a single, large diaphragm or a plurality of smaller diaphragms. It should also be understood that the placement of the diaphragm and/or piezoelectric membrane is not limited to the proximal end region of the LCP. In some cases, the diaphragm and/or piezoelectric membrane may be positioned in or adjacent to a sidewall and/or near the distal end region.

In some cases, the diaphragms and/or piezoelectric membranes may include contours configured to increase the sensitivity and/or linearity of the diaphragms and/or piezoelectric membranes. Some illustrative contours may include, but are not limited to, a concave surface, a convex surface, an undulating surface, a generally convex surface having a generally concave central region, etc. It is contemplated that the contours may be tuned for the application and/or placement of the device.

Regardless of the placement location of the LCP, some static pressure may be applied to the diaphragm and/or piezoelectric membrane upon implantation of the device. This may cause the diaphragm and/or piezoelectric membrane to flex from its un-implanted configuration. The LCP may be configured to detect changes in pressure over time which are indicated by a movement of the diaphragm. As such, and in some cases, it may be desirable to pre-tune the diaphragm and/or piezoelectric membrane to optimize the pressure range of the diaphragm and/or piezoelectric membrane when the LCP is implanted. This may be accomplished by deforming the diaphragm and/or piezoelectric membrane during manufacture in a direction opposite to the static pressure exerted by the chamber of the heart such that the diaphragm and/or piezoelectric membrane are in a neutral configuration after implantation (as opposed to flexed inwards under the static pressure of the implantation chamber).

Those skilled in the art will recognize that the present disclosure may be manifested in a variety of forms other than the specific examples described and contemplated herein. For instance, as described herein, various examples include one or more modules described as performing various functions. However, other examples may include additional modules that split the described functions up over more modules than that described herein. Additionally, other examples may consolidate the described functions into fewer modules. Accordingly, departure in form and detail may be made without departing from the scope and spirit of the present disclosure as described in the appended claims.

Claims

1. An Implantable Medical Device (IMD) for implantation in a ventricle of a heart, wherein the heart includes an atrium that contracts to supply blood to the ventricle, the IMD comprising: an elongated housing having a midpoint with a proximal region extending proximally of the midpoint and a distal region extending distally of the midpoint, the distal region having at a distal end;a first electrode exposed to the environment outside of the housing along the distal end of the housing;a second electrode situated in the proximal region of the housing and exposed to the environment outside of the housing;a pressure sensor housed by the housing, the pressure sensor is structured to sense a change in pressure in the ventricle of the heart that is indicative of a contraction of the atrium of the heart, and in response, produce an output signal, wherein the pressure sensor includes a sensing diaphragm that is encompassed entirely in the proximal region of the housing;control circuitry housed by the housing and operatively coupled to the first electrode, the second electrode and the pressure sensor, the control circuitry is configured to identify an atrial contraction of the heart based at least in part on the output signal of the pressure sensor; andcommunication circuitry operatively coupled to the control circuitry, the communication circuitry configured to send information to a remote device that is based at least in part on the identified atrial contraction of the heart.
2. The IMD of claim 1, wherein the communication circuitry is configured to send information to the remote device via conducted communication.
3. A leadless cardiac pacemaker (LCP) for implantation in a ventricle of a heart, wherein the heart includes an atrium that contracts to supply blood to the ventricle, the LCP configured to sense cardiac activity and to deliver pacing therapy to the ventricle of the heart, the LCP comprising: an elongated housing having a midpoint with a proximal region extending proximally of the midpoint and a distal region extending distally of the midpoint, the distal region having at a distal end;a first electrode exposed to the environment outside of the housing along the distal end of the housing;a second electrode situated in the proximal region of the housing and exposed to the environment outside of the housing;a fixation member proximate the distal end of the housing for fixing the distal end of the housing relative to a heart wall of the ventricle at an implant site with the first electrode held in physical and electrical engagement with the heart wall at the implant site, and with the proximal region of the housing extending away from the heart wall at the implant site;a pressure sensor structured to sense a change in pressure in the ventricle of the heart that is caused by a contraction of the atrium of the heart, and in response, produce an electrical A-wave output signal, wherein the pressure sensor includes a diaphragm that is configured to sense the pressure in the ventricle of the heart, wherein the diaphragm is encompassed entirely in the proximal region of the housing;circuitry housed by the housing and operatively coupled to the first electrode, the second electrode and the pressure sensor, the circuitry is configured to deliver a pacing therapy to the ventricle of the heart via the first electrode and the second electrode;the circuitry is configured to identify an atrial contraction of the heart based at least in part on the electrical A-wave output signal from the pressure sensor; andthe circuitry is configured to adapt a timing of delivery of at least part of the pacing therapy delivered to the ventricle of the heart based at least in part on the identified atrial contraction of the heart.
4. The LCP of claim 3, wherein the diaphragm is configured to move by an amount that is dependent on an applied input pressure, and wherein the pressure sensor produces an electrical output signal that is dependent on the amount of movement of the diaphragm.
5. The LCP of claim 4, wherein the circuitry is configured to determine one or more arrhythmias based at least in part on the electrical output signal produced by the pressure sensor.
6. The LCP of claim 4, wherein the circuitry is configured to monitor the electrical output signal of the pressure sensor to identify a progression of a chronic heart disease.
7. The LCP of claim 4, further comprising communication circuitry configured to send information to a remote device that is based at least in part on the electrical output signal of the pressure sensor.
8. The LCP of claim 4, wherein the pressure sensor further comprises a piezo material carried by the diaphragm that causes the electrical output signal of the pressure sensor to correspond to the amount of movement of the diaphragm.
9. The LCP of claim 4, wherein the proximal region of the housing comprises a thinned wall region that forms at least part of the diaphragm.
10. The LCP of claim 4, wherein the housing defines a fluid cavity that is filled with an incompressible fluid, and wherein the diaphragm is exposed to the incompressible fluid in the fluid cavity.
11. The LCP of claim 3, wherein the pacing therapy comprises a Cardiac Resynchronization Therapy (CRT).
12. The LCP of claim 3, wherein the pacing therapy comprises a Bradycardia Therapy.
13. The LCP of claim 3, wherein the pacing therapy comprises an Anti-Tachycardia Pacing (ATP) Therapy.
14. The LCP of claim 3, wherein the first electrode and the second electrode are each situated along an outer surface of the housing.
15. A leadless cardiac pacemaker (LCP) for implantation in a ventricle of a patient's heart, wherein the patient's heart includes an atrium that contracts to supply blood to the ventricle, the LCP comprising: an elongated housing having a midpoint with a proximal region extending proximally of the midpoint and a distal region extending distally of the midpoint, the distal region having at a distal end;a first electrode exposed to the environment outside of the housing along the distal end of the housing;a second electrode situated in the proximal region of the housing and exposed to the environment outside of the housing;a pressure sensor configured to produce an output signal that is responsive to a change in pressure in the ventricle of the patient's heart that is indicative of a contraction of the atrium of the patient's heart, wherein the pressure sensor includes a sensing diaphragm that is encompassed entirely in the proximal region of the housing; andcircuitry housed by the housing in operative communication with the first electrode, the second electrode and the pressure sensor, wherein the circuitry is configured to detect the change in pressure in the ventricle of the patient's heart that is indicative of the contraction of the atrium of the patient's heart from the output signal of the pressure sensor, the circuitry is configured to deliver an electrostimulation therapy to the patient's heart via the first electrode and the second electrode that is based, at least in part, on the detected change in pressure in the ventricle of the patient's heart that is indicative of the contraction of the atrium of the patient's heart.
16. The LCP of claim 15, wherein the sensing diaphragm is structured to be sensitive to the change in the pressure in the ventricle of the patient's heart indicative of the contraction of the atrium of the patient's heart.
17. The LCP of claim 15, wherein the circuitry is configured to determine one or more arrhythmias based at least in part on the output signal produced by the pressure sensor.
18. The LCP of claim 15, further comprising communication circuitry configured to send information to a remote device that is based at least in part on the output signal of the pressure sensor.

Parent Case Info

This is a continuation of co-pending U.S. patent application Ser. No. 16/104,370, filed Aug. 17, 2018, which claims the benefit of U.S. Provisional Patent Application Ser. No. 62/547,458 filed on Aug. 18, 2017, both of which are incorporated herein by reference.

US Referenced Citations (1339)

Number	Name	Date	Kind
3835864	Rasor et al.	Sep 1974	A
3943936	Rasor et al.	Mar 1976	A
4142530	Wittkampf	Mar 1979	A
4151513	Menken et al.	Apr 1979	A
4157720	Greatbatch	Jun 1979	A
RE30366	Rasor et al.	Aug 1980	E
4243045	Maas	Jan 1981	A
4250884	Hartlaub et al.	Feb 1981	A
4256115	Bilitch	Mar 1981	A
4263919	Levin	Apr 1981	A
4310000	Lindemans	Jan 1982	A
4312354	Walters	Jan 1982	A
4323081	Wiebusch	Apr 1982	A
4357946	Dutcher et al.	Nov 1982	A
4365639	Goldreyer	Dec 1982	A
4440173	Dudziak et al.	Apr 1984	A
4476868	Thompson	Oct 1984	A
4522208	Buffet	Jun 1985	A
4537200	Widrow	Aug 1985	A
4556063	Thompson et al.	Dec 1985	A
4562841	Brockway et al.	Jan 1986	A
4593702	Kepski et al.	Jun 1986	A
4593955	Leiber	Jun 1986	A
4630611	King	Dec 1986	A
4635639	Hakala et al.	Jan 1987	A
4674508	DeCote	Jun 1987	A
4712554	Garson	Dec 1987	A
4729376	DeCote	Mar 1988	A
4754753	King	Jul 1988	A
4759366	Callaghan	Jul 1988	A
4776338	Lekholm et al.	Oct 1988	A
4787389	Tarjan	Nov 1988	A
4793353	Borkan	Dec 1988	A
4819662	Heil et al.	Apr 1989	A
4858610	Callaghan et al.	Aug 1989	A
4886064	Strandberg	Dec 1989	A
4887609	Cole	Dec 1989	A
4928688	Mower	May 1990	A
4967746	Vandegriff	Nov 1990	A
4987897	Funke	Jan 1991	A
4989602	Sholder et al.	Feb 1991	A
5012806	De Bellis	May 1991	A
5036849	Hauck et al.	Aug 1991	A
5040534	Mann et al.	Aug 1991	A
5058581	Silvian	Oct 1991	A
5078134	Heilman et al.	Jan 1992	A
5109845	Yuuchi et al.	May 1992	A
5113859	Funke	May 1992	A
5113869	Nappholz et al.	May 1992	A
5117824	Keimel et al.	Jun 1992	A
5127401	Grevious et al.	Jul 1992	A
5133353	Hauser	Jul 1992	A
5144950	Stoop et al.	Sep 1992	A
5170784	Ramon et al.	Dec 1992	A
5179945	Van Hofwegen et al.	Jan 1993	A
5193539	Schulman et al.	Mar 1993	A
5193540	Schulman et al.	Mar 1993	A
5241961	Henry	Sep 1993	A
5243977	Trabucco et al.	Sep 1993	A
5259387	DePinto	Nov 1993	A
5269326	Verrier	Dec 1993	A
5284136	Hauck et al.	Feb 1994	A
5300107	Stokes et al.	Apr 1994	A
5301677	Hsung	Apr 1994	A
5305760	McKown et al.	Apr 1994	A
5312439	Loeb	May 1994	A
5313953	Yomtov et al.	May 1994	A
5314459	Swanson et al.	May 1994	A
5318597	Hauck et al.	Jun 1994	A
5324316	Schulman et al.	Jun 1994	A
5331966	Bennett et al.	Jul 1994	A
5334222	Salo et al.	Aug 1994	A
5342408	deCoriolis et al.	Aug 1994	A
5370667	Alt	Dec 1994	A
5372606	Lang et al.	Dec 1994	A
5376106	Stahmann et al.	Dec 1994	A
5383915	Adams	Jan 1995	A
5388578	Yomtov et al.	Feb 1995	A
5404877	Nolan et al.	Apr 1995	A
5405367	Schulman et al.	Apr 1995	A
5411031	Yomtov	May 1995	A
5411525	Swanson et al.	May 1995	A
5411535	Fujii et al.	May 1995	A
5456691	Snell	Oct 1995	A
5458622	Alt	Oct 1995	A
5466246	Silvian	Nov 1995	A
5468254	Hahn et al.	Nov 1995	A
5472453	Alt	Dec 1995	A
5522866	Fernald	Jun 1996	A
5535752	Halperin et al.	Jul 1996	A
5540727	Tockman et al.	Jul 1996	A
5545186	Olson et al.	Aug 1996	A
5545202	Dahl et al.	Aug 1996	A
5571146	Jones et al.	Nov 1996	A
5591214	Lu	Jan 1997	A
5620466	Haefner et al.	Apr 1997	A
5634938	Swanson et al.	Jun 1997	A
5649968	Alt et al.	Jul 1997	A
5662688	Haefner et al.	Sep 1997	A
5674259	Gray	Oct 1997	A
5683426	Greenhut et al.	Nov 1997	A
5683432	Goedeke et al.	Nov 1997	A
5702427	Ecker et al.	Dec 1997	A
5706823	Wodlinger	Jan 1998	A
5709215	Perttu et al.	Jan 1998	A
5720770	Nappholz et al.	Feb 1998	A
5728154	Crossett et al.	Mar 1998	A
5741314	Daly et al.	Apr 1998	A
5741315	Lee et al.	Apr 1998	A
5752976	Duffin et al.	May 1998	A
5752977	Grevious et al.	May 1998	A
5755736	Gillberg et al.	May 1998	A
5759199	Snell et al.	Jun 1998	A
5774501	Halpern et al.	Jun 1998	A
5792195	Carlson et al.	Aug 1998	A
5792202	Rueter	Aug 1998	A
5792203	Schroeppel	Aug 1998	A
5792205	Alt et al.	Aug 1998	A
5792208	Gray	Aug 1998	A
5814089	Stokes et al.	Sep 1998	A
5827216	Igo et al.	Oct 1998	A
5836985	Rostami et al.	Nov 1998	A
5836987	Baumann et al.	Nov 1998	A
5842977	Lesho et al.	Dec 1998	A
5855593	Olson et al.	Jan 1999	A
5873894	Vandegriff et al.	Feb 1999	A
5891184	Lee et al.	Apr 1999	A
5897586	Molina	Apr 1999	A
5899876	Flower	May 1999	A
5899928	Sholder et al.	May 1999	A
5919214	Ciciarelli et al.	Jul 1999	A
5935078	Feierbach	Aug 1999	A
5941906	Barreras, Sr. et al.	Aug 1999	A
5944744	Paul et al.	Aug 1999	A
5954757	Gray	Sep 1999	A
5978713	Prutchi et al.	Nov 1999	A
5991660	Goyal	Nov 1999	A
5991661	Park et al.	Nov 1999	A
5999848	Gord et al.	Dec 1999	A
5999857	Weijand et al.	Dec 1999	A
6016445	Baura	Jan 2000	A
6026320	Carlson et al.	Feb 2000	A
6029085	Olson et al.	Feb 2000	A
6041250	DePinto	Mar 2000	A
6044298	Salo et al.	Mar 2000	A
6044300	Gray	Mar 2000	A
6055454	Heemels	Apr 2000	A
6073050	Griffith	Jun 2000	A
6076016	Feierbach	Jun 2000	A
6077236	Cunningham	Jun 2000	A
6080187	Alt et al.	Jun 2000	A
6083248	Thompson	Jul 2000	A
6106551	Crossett et al.	Aug 2000	A
6115636	Ryan	Sep 2000	A
6128526	Stadler et al.	Oct 2000	A
6141581	Olson et al.	Oct 2000	A
6141588	Cox et al.	Oct 2000	A
6141592	Pauly	Oct 2000	A
6144879	Gray	Nov 2000	A
6162195	Igo et al.	Dec 2000	A
6164284	Schulman et al.	Dec 2000	A
6167310	Grevious	Dec 2000	A
6201993	Kruse et al.	Mar 2001	B1
6208894	Schulman et al.	Mar 2001	B1
6211799	Post et al.	Apr 2001	B1
6221011	Bardy	Apr 2001	B1
6223081	Kerver	Apr 2001	B1
6240316	Richmond et al.	May 2001	B1
6240317	Villaseca et al.	May 2001	B1
6256534	Dahl	Jul 2001	B1
6259947	Olson et al.	Jul 2001	B1
6266558	Gozani et al.	Jul 2001	B1
6266567	Ishikawa et al.	Jul 2001	B1
6270457	Bardy	Aug 2001	B1
6272377	Sweeney et al.	Aug 2001	B1
6273856	Sun et al.	Aug 2001	B1
6277072	Bardy	Aug 2001	B1
6280380	Bardy	Aug 2001	B1
6285907	Kramer et al.	Sep 2001	B1
6292698	Duffin et al.	Sep 2001	B1
6295473	Rosar	Sep 2001	B1
6297943	Carson	Oct 2001	B1
6298271	Weijand	Oct 2001	B1
6307751	Bodony et al.	Oct 2001	B1
6312378	Bardy	Nov 2001	B1
6314323	Ekwall	Nov 2001	B1
6315721	Schulman et al.	Nov 2001	B2
6336903	Bardy	Jan 2002	B1
6345202	Richmond et al.	Feb 2002	B2
6351667	Godie	Feb 2002	B1
6351669	Hartley et al.	Feb 2002	B1
6353759	Hartley et al.	Mar 2002	B1
6358203	Bardy	Mar 2002	B2
6361780	Ley et al.	Mar 2002	B1
6368284	Bardy	Apr 2002	B1
6371922	Baumann et al.	Apr 2002	B1
6398728	Bardy	Jun 2002	B1
6400982	Sweeney et al.	Jun 2002	B2
6400990	Silvian	Jun 2002	B1
6408208	Sun	Jun 2002	B1
6409674	Brockway et al.	Jun 2002	B1
6411848	Kramer et al.	Jun 2002	B2
6424865	Ding	Jul 2002	B1
6434429	Kraus et al.	Aug 2002	B1
6438410	Hsu et al.	Aug 2002	B2
6438417	Rockwell et al.	Aug 2002	B1
6438421	Stahmann et al.	Aug 2002	B1
6440066	Bardy	Aug 2002	B1
6441747	Khair et al.	Aug 2002	B1
6442426	Kroll	Aug 2002	B1
6442432	Lee	Aug 2002	B2
6443891	Grevious	Sep 2002	B1
6445953	Bulkes et al.	Sep 2002	B1
6453200	Koslar	Sep 2002	B1
6459929	Hopper et al.	Oct 2002	B1
6470215	Kraus et al.	Oct 2002	B1
6471645	Warkentin et al.	Oct 2002	B1
6480745	Nelson et al.	Nov 2002	B2
6487443	Olson et al.	Nov 2002	B2
6490487	Kraus et al.	Dec 2002	B1
6498951	Larson et al.	Dec 2002	B1
6505077	Kast et al.	Jan 2003	B1
6507755	Gozani et al.	Jan 2003	B1
6507759	Prutchi et al.	Jan 2003	B1
6512940	Brabec et al.	Jan 2003	B1
6522915	Ceballos et al.	Feb 2003	B1
6526311	Begemann	Feb 2003	B2
6539253	Thompson et al.	Mar 2003	B2
6542775	Ding et al.	Apr 2003	B2
6553258	Stahmann et al.	Apr 2003	B2
6561975	Pool et al.	May 2003	B1
6564807	Schulman et al.	May 2003	B1
6574506	Kramer et al.	Jun 2003	B2
6584351	Ekwall	Jun 2003	B1
6584352	Combs et al.	Jun 2003	B2
6597948	Rockwell et al.	Jul 2003	B1
6597951	Kramer et al.	Jul 2003	B2
6622046	Fraley et al.	Sep 2003	B2
6628985	Sweeney et al.	Sep 2003	B2
6647292	Bardy et al.	Nov 2003	B1
6666844	Igo et al.	Dec 2003	B1
6689117	Sweeney et al.	Feb 2004	B2
6690959	Thompson	Feb 2004	B2
6694189	Begemann	Feb 2004	B2
6704602	Berg et al.	Mar 2004	B2
6718212	Parry et al.	Apr 2004	B2
6721597	Bardy et al.	Apr 2004	B1
6738670	Almendinger et al.	May 2004	B1
6746797	Benson et al.	Jun 2004	B2
6749566	Russ	Jun 2004	B2
6758810	Lebel et al.	Jul 2004	B2
6763269	Cox	Jul 2004	B2
6778860	Ostroff et al.	Aug 2004	B2
6788971	Sloman et al.	Sep 2004	B1
6788974	Bardy et al.	Sep 2004	B2
6804558	Haller et al.	Oct 2004	B2
6807442	Myklebust et al.	Oct 2004	B1
6847844	Sun et al.	Jan 2005	B2
6871088	Chinchoy	Mar 2005	B2
6871095	Stahmann et al.	Mar 2005	B2
6878112	Linberg et al.	Apr 2005	B2
6885889	Chinchoy	Apr 2005	B2
6892094	Ousdigian et al.	May 2005	B2
6897788	Khair et al.	May 2005	B2
6904315	Panken et al.	Jun 2005	B2
6922592	Thompson et al.	Jul 2005	B2
6931282	Esler	Aug 2005	B2
6934585	Schloss et al.	Aug 2005	B1
6957107	Rogers et al.	Oct 2005	B2
6978176	Lattouf	Dec 2005	B2
6985773	Von Arx et al.	Jan 2006	B2
6990375	Kloss et al.	Jan 2006	B2
7001366	Ballard	Feb 2006	B2
7003350	Denker et al.	Feb 2006	B2
7006864	Echt et al.	Feb 2006	B2
7013178	Reinke et al.	Mar 2006	B2
7027871	Burnes et al.	Apr 2006	B2
7050849	Echt et al.	May 2006	B2
7060031	Webb et al.	Jun 2006	B2
7063693	Guenst	Jun 2006	B2
7082336	Ransbury et al.	Jul 2006	B2
7085606	Flach et al.	Aug 2006	B2
7092758	Sun et al.	Aug 2006	B2
7110824	Amundson et al.	Sep 2006	B2
7120504	Osypka	Oct 2006	B2
7130681	Gebhardt et al.	Oct 2006	B2
7139613	Reinke et al.	Nov 2006	B2
7142912	Wagner et al.	Nov 2006	B2
7142917	Fukui	Nov 2006	B2
7146225	Guenst et al.	Dec 2006	B2
7146226	Lau et al.	Dec 2006	B2
7149575	Ostroff et al.	Dec 2006	B2
7149581	Goedeke	Dec 2006	B2
7149588	Lau et al.	Dec 2006	B2
7158839	Lau	Jan 2007	B2
7162307	Patrias	Jan 2007	B2
7164952	Lau et al.	Jan 2007	B2
7177700	Cox	Feb 2007	B1
7181505	Haller et al.	Feb 2007	B2
7184830	Echt et al.	Feb 2007	B2
7186214	Ness	Mar 2007	B2
7189204	Ni et al.	Mar 2007	B2
7191015	Lamson et al.	Mar 2007	B2
7200437	Nabutovsky et al.	Apr 2007	B1
7200439	Zdeblick et al.	Apr 2007	B2
7206423	Feng et al.	Apr 2007	B1
7209785	Kim et al.	Apr 2007	B2
7209790	Thompson et al.	Apr 2007	B2
7211884	Davis et al.	May 2007	B1
7212861	Park et al.	May 2007	B1
7212871	Morgan	May 2007	B1
7226440	Gelfand et al.	Jun 2007	B2
7228183	Sun et al.	Jun 2007	B2
7236821	Cates et al.	Jun 2007	B2
7236829	Farazi et al.	Jun 2007	B1
7254448	Almendinger et al.	Aug 2007	B2
7260436	Kilgore et al.	Aug 2007	B2
7270669	Sra	Sep 2007	B1
7272448	Morgan et al.	Sep 2007	B1
7277755	Falkenberg et al.	Oct 2007	B1
7280872	Mosesov et al.	Oct 2007	B1
7286875	Park et al.	Oct 2007	B1
7288096	Chin	Oct 2007	B2
7289847	Gill et al.	Oct 2007	B1
7289852	Helfinstine et al.	Oct 2007	B2
7289853	Campbell et al.	Oct 2007	B1
7289855	Nghiem et al.	Oct 2007	B2
7302294	Kamath et al.	Nov 2007	B2
7305266	Kroll	Dec 2007	B1
7310556	Bulkes	Dec 2007	B2
7319905	Morgan et al.	Jan 2008	B1
7321798	Muhlenberg et al.	Jan 2008	B2
7333853	Mazar et al.	Feb 2008	B2
7336994	Hettrick et al.	Feb 2008	B2
7347819	Lebel et al.	Mar 2008	B2
7366572	Heruth et al.	Apr 2008	B2
7373207	Lattouf	May 2008	B2
7376458	Palreddy et al.	May 2008	B2
7384403	Sherman	Jun 2008	B2
7386342	Falkenberg et al.	Jun 2008	B1
7392090	Sweeney et al.	Jun 2008	B2
7406105	DelMain et al.	Jul 2008	B2
7406349	Seeberger et al.	Jul 2008	B2
7410497	Hastings et al.	Aug 2008	B2
7418868	Karicherla et al.	Sep 2008	B1
7425200	Brockway et al.	Sep 2008	B2
7433739	Salys et al.	Oct 2008	B1
7477935	Palreddy et al.	Jan 2009	B2
7496409	Greenhut et al.	Feb 2009	B2
7496410	Heil	Feb 2009	B2
7502652	Gaunt et al.	Mar 2009	B2
7512448	Malick et al.	Mar 2009	B2
7515969	Tockman et al.	Apr 2009	B2
7526342	Chin et al.	Apr 2009	B2
7529589	Williams et al.	May 2009	B2
7532933	Hastings et al.	May 2009	B2
7536222	Bardy et al.	May 2009	B2
7536224	Ritscher et al.	May 2009	B2
7539541	Quiles et al.	May 2009	B2
7544197	Kelsch et al.	Jun 2009	B2
7558631	Cowan et al.	Jul 2009	B2
7565195	Kroll et al.	Jul 2009	B1
7580746	Gilkerson et al.	Aug 2009	B2
7584002	Burnes et al.	Sep 2009	B2
7590455	Heruth et al.	Sep 2009	B2
7596412	Kroll	Sep 2009	B1
7606621	Brisken et al.	Oct 2009	B2
7610088	Chinchoy	Oct 2009	B2
7610092	Cowan et al.	Oct 2009	B2
7610099	Almendinger et al.	Oct 2009	B2
7610104	Kaplan et al.	Oct 2009	B2
7616991	Mann et al.	Nov 2009	B2
7617001	Penner et al.	Nov 2009	B2
7617007	Williams et al.	Nov 2009	B2
7630763	Kwok et al.	Dec 2009	B2
7630767	Poore et al.	Dec 2009	B1
7634313	Kroll et al.	Dec 2009	B1
7637867	Zdeblick	Dec 2009	B2
7640060	Zdeblick	Dec 2009	B2
7647109	Hastings	Jan 2010	B2
7650186	Hastings et al.	Jan 2010	B2
7657311	Bardy et al.	Feb 2010	B2
7668596	Von Arx et al.	Feb 2010	B2
7676266	Kroll	Mar 2010	B1
7682316	Anderson et al.	Mar 2010	B2
7691047	Ferrari	Apr 2010	B2
7702389	Czygan et al.	Apr 2010	B2
7702392	Echt et al.	Apr 2010	B2
7713194	Zdeblick	May 2010	B2
7713195	Zdeblick	May 2010	B2
7729783	Michels et al.	Jun 2010	B2
7734333	Ghanem et al.	Jun 2010	B2
7734343	Ransbury et al.	Jun 2010	B2
7738958	Zdeblick et al.	Jun 2010	B2
7738964	Von Arx et al.	Jun 2010	B2
7742812	Ghanem et al.	Jun 2010	B2
7742816	Masoud et al.	Jun 2010	B2
7742822	Masoud et al.	Jun 2010	B2
7743151	Vallapureddy et al.	Jun 2010	B2
7747335	Williams	Jun 2010	B2
7751881	Cowan et al.	Jul 2010	B2
7758521	Morris et al.	Jul 2010	B2
7761150	Ghanem et al.	Jul 2010	B2
7761164	Verhoef et al.	Jul 2010	B2
7765001	Echt et al.	Jul 2010	B2
7769452	Ghanem et al.	Aug 2010	B2
7783340	Sanghera et al.	Aug 2010	B2
7783362	Whitehurst et al.	Aug 2010	B2
7792588	Harding	Sep 2010	B2
7797059	Bornzin et al.	Sep 2010	B1
7801596	Fischell et al.	Sep 2010	B2
7809438	Echt et al.	Oct 2010	B2
7809441	Kane et al.	Oct 2010	B2
7840281	Kveen et al.	Nov 2010	B2
7844331	Li et al.	Nov 2010	B2
7844348	Swoyer et al.	Nov 2010	B2
7846088	Ness	Dec 2010	B2
7848815	Brisken et al.	Dec 2010	B2
7848823	Drasler et al.	Dec 2010	B2
7860455	Fukumoto et al.	Dec 2010	B2
7871433	Lattouf	Jan 2011	B2
7877136	Moffitt et al.	Jan 2011	B1
7877142	Moaddeb et al.	Jan 2011	B2
7881786	Jackson	Feb 2011	B2
7881798	Miesel et al.	Feb 2011	B2
7881810	Chitre et al.	Feb 2011	B1
7890173	Brisken et al.	Feb 2011	B2
7890181	Denzene et al.	Feb 2011	B2
7890192	Kelsch et al.	Feb 2011	B1
7894885	Bartal et al.	Feb 2011	B2
7894894	Stadler et al.	Feb 2011	B2
7894907	Cowan et al.	Feb 2011	B2
7894910	Cowan et al.	Feb 2011	B2
7894915	Chitre et al.	Feb 2011	B1
7899537	Kroll et al.	Mar 2011	B1
7899541	Cowan et al.	Mar 2011	B2
7899542	Cowan et al.	Mar 2011	B2
7899554	Williams et al.	Mar 2011	B2
7901360	Yang et al.	Mar 2011	B1
7904170	Harding	Mar 2011	B2
7907993	Ghanem et al.	Mar 2011	B2
7920928	Yang et al.	Apr 2011	B1
7925343	Min et al.	Apr 2011	B1
7930022	Zhang et al.	Apr 2011	B2
7930040	Kelsch et al.	Apr 2011	B1
7937135	Ghanem et al.	May 2011	B2
7937148	Jacobson	May 2011	B2
7937161	Hastings et al.	May 2011	B2
7941214	Kleckner et al.	May 2011	B2
7945333	Jacobson	May 2011	B2
7946997	Hübinette	May 2011	B2
7949404	Hill	May 2011	B2
7949405	Feher	May 2011	B2
7953486	Daum et al.	May 2011	B2
7953493	Fowler et al.	May 2011	B2
7962202	Bhunia	Jun 2011	B2
7974702	Fain et al.	Jul 2011	B1
7979136	Young et al.	Jul 2011	B2
7983753	Severin	Jul 2011	B2
7991467	Markowitz et al.	Aug 2011	B2
7991471	Ghanem et al.	Aug 2011	B2
7996087	Cowan et al.	Aug 2011	B2
8000791	Sunagawa et al.	Aug 2011	B2
8000807	Morris et al.	Aug 2011	B2
8001975	DiSilvestro et al.	Aug 2011	B2
8002700	Ferek-Petric et al.	Aug 2011	B2
8010209	Jacobson	Aug 2011	B2
8019419	Panescu et al.	Sep 2011	B1
8019434	Quiles et al.	Sep 2011	B2
8027727	Freeberg	Sep 2011	B2
8027729	Sunagawa et al.	Sep 2011	B2
8032219	Neumann et al.	Oct 2011	B2
8036743	Savage et al.	Oct 2011	B2
8046079	Bange et al.	Oct 2011	B2
8046080	Von Arx et al.	Oct 2011	B2
8050297	DelMain et al.	Nov 2011	B2
8050759	Stegemann et al.	Nov 2011	B2
8050774	Kveen et al.	Nov 2011	B2
8055345	Li et al.	Nov 2011	B2
8055350	Roberts	Nov 2011	B2
8060212	Rios et al.	Nov 2011	B1
8065018	Haubrich et al.	Nov 2011	B2
8073542	Doerr	Dec 2011	B2
8078278	Penner	Dec 2011	B2
8078283	Cowan et al.	Dec 2011	B2
8079959	Sanghera et al.	Dec 2011	B2
8095123	Gray	Jan 2012	B2
8102789	Rosar et al.	Jan 2012	B2
8103359	Reddy	Jan 2012	B2
8103361	Moser	Jan 2012	B2
8112148	Giftakis et al.	Feb 2012	B2
8114021	Robertson et al.	Feb 2012	B2
8116867	Ostroff	Feb 2012	B2
8121680	Falkenberg et al.	Feb 2012	B2
8123684	Zdeblick	Feb 2012	B2
8126545	Flach et al.	Feb 2012	B2
8131334	Lu et al.	Mar 2012	B2
8140161	Willerton et al.	Mar 2012	B2
8150521	Crowley et al.	Apr 2012	B2
8157813	Ko et al.	Apr 2012	B2
8160672	Kim et al.	Apr 2012	B2
8160702	Mann et al.	Apr 2012	B2
8160704	Freeberg	Apr 2012	B2
8165694	Carbanaru et al.	Apr 2012	B2
8175715	Cox	May 2012	B1
8180451	Hickman et al.	May 2012	B2
8185213	Kveen et al.	May 2012	B2
8187161	Li et al.	May 2012	B2
8195293	Limousin et al.	Jun 2012	B2
8195308	Frank et al.	Jun 2012	B2
8200341	Sanghera et al.	Jun 2012	B2
8204595	Pianca et al.	Jun 2012	B2
8204605	Hastings et al.	Jun 2012	B2
8209014	Doerr	Jun 2012	B2
8214043	Matos	Jul 2012	B2
8224244	Kim et al.	Jul 2012	B2
8229556	Li	Jul 2012	B2
8233985	Bulkes et al.	Jul 2012	B2
8262578	Bharmi et al.	Sep 2012	B1
8265748	Liu et al.	Sep 2012	B2
8265757	Mass et al.	Sep 2012	B2
8280521	Haubrich et al.	Oct 2012	B2
8285387	Utsi et al.	Oct 2012	B2
8290598	Boon et al.	Oct 2012	B2
8290600	Hastings et al.	Oct 2012	B2
8295939	Jacobson	Oct 2012	B2
8301254	Mosesov et al.	Oct 2012	B2
8306621	Kim et al.	Nov 2012	B2
8315701	Cowan et al.	Nov 2012	B2
8315708	Berthelsdorf et al.	Nov 2012	B2
8321021	Kisker et al.	Nov 2012	B2
8321036	Brockway et al.	Nov 2012	B2
8332034	Patangay et al.	Dec 2012	B2
8332036	Hastings et al.	Dec 2012	B2
8335563	Stessman	Dec 2012	B2
8335568	Heruth et al.	Dec 2012	B2
8340750	Prakash et al.	Dec 2012	B2
8340780	Hastings et al.	Dec 2012	B2
8352025	Jacobson	Jan 2013	B2
8352028	Wenger	Jan 2013	B2
8352038	Mao et al.	Jan 2013	B2
8359098	Lund et al.	Jan 2013	B2
8364261	Stubbs et al.	Jan 2013	B2
8364276	Willis	Jan 2013	B2
8369959	Meskens	Feb 2013	B2
8369962	Abrahamson	Feb 2013	B2
8380320	Spital	Feb 2013	B2
8386051	Rys	Feb 2013	B2
8391981	Mosesov	Mar 2013	B2
8391990	Smith et al.	Mar 2013	B2
8406874	Liu et al.	Mar 2013	B2
8406879	Shuros et al.	Mar 2013	B2
8406886	Gaunt et al.	Mar 2013	B2
8412352	Griswold et al.	Apr 2013	B2
8417340	Goossen	Apr 2013	B2
8417341	Freeberg	Apr 2013	B2
8423149	Hennig	Apr 2013	B2
8428722	Verhoef et al.	Apr 2013	B2
8433402	Ruben et al.	Apr 2013	B2
8433409	Johnson et al.	Apr 2013	B2
8433420	Bange et al.	Apr 2013	B2
8447412	Dal Molin et al.	May 2013	B2
8452413	Young et al.	May 2013	B2
8457740	Osche	Jun 2013	B2
8457742	Jacobson	Jun 2013	B2
8457744	Janzig et al.	Jun 2013	B2
8457761	Wariar	Jun 2013	B2
8478399	Degroot et al.	Jul 2013	B2
8478400	Hettrick et al.	Jul 2013	B2
8478407	Demmer et al.	Jul 2013	B2
8478408	Hastings et al.	Jul 2013	B2
8478431	Griswold et al.	Jul 2013	B2
8483843	Sanghera et al.	Jul 2013	B2
8494632	Sun et al.	Jul 2013	B2
8521265	Volkron et al.	Jul 2013	B2
8504156	Bonner et al.	Aug 2013	B2
8509910	Sowder et al.	Aug 2013	B2
8515559	Roberts et al.	Aug 2013	B2
8525340	Eckhardt et al.	Sep 2013	B2
8527068	Ostroff	Sep 2013	B2
8532790	Griswold	Sep 2013	B2
8538526	Stahmann et al.	Sep 2013	B2
8541131	Lund et al.	Sep 2013	B2
8543205	Ostroff	Sep 2013	B2
8547248	Zdeblick et al.	Oct 2013	B2
8548605	Ollivier	Oct 2013	B2
8554333	Wu et al.	Oct 2013	B2
8565878	Allavatam et al.	Oct 2013	B2
8565882	Matos	Oct 2013	B2
8565897	Regnier et al.	Oct 2013	B2
8571678	Wang	Oct 2013	B2
8577327	Makdissi et al.	Nov 2013	B2
8588926	Moore et al.	Nov 2013	B2
8612002	Faltys et al.	Dec 2013	B2
8615310	Khairkhahan et al.	Dec 2013	B2
8626280	Allavatam et al.	Jan 2014	B2
8626294	Sheldon et al.	Jan 2014	B2
8626310	Barror et al.	Jan 2014	B2
8634908	Cowan	Jan 2014	B2
8634912	Bornzin et al.	Jan 2014	B2
8634919	Hou et al.	Jan 2014	B1
8639335	Peichel et al.	Jan 2014	B2
8644934	Hastings et al.	Feb 2014	B2
8649859	Smith et al.	Feb 2014	B2
8670842	Bornzin et al.	Mar 2014	B1
8676319	Knoll	Mar 2014	B2
8676335	Katoozi et al.	Mar 2014	B2
8700173	Edlund	Apr 2014	B2
8700181	Bornzin et al.	Apr 2014	B2
8705599	dal Molin et al.	Apr 2014	B2
8718766	Wahlberg	May 2014	B2
8718773	Willis et al.	May 2014	B2
8725260	Shuros et al.	May 2014	B2
8738133	Shuros et al.	May 2014	B2
8738147	Hastings et al.	May 2014	B2
8744555	Allavatam et al.	Jun 2014	B2
8744572	Greenhut et al.	Jun 2014	B1
8747314	Stahmann et al.	Jun 2014	B2
8755884	Demmer et al.	Jun 2014	B2
8758365	Bonner et al.	Jun 2014	B2
8768483	Schmitt et al.	Jul 2014	B2
8774572	Hamamoto	Jul 2014	B2
8781605	Bornzin et al.	Jul 2014	B2
8788035	Jacobson	Jul 2014	B2
8788053	Jacobson	Jul 2014	B2
8798740	Samade et al.	Aug 2014	B2
8798745	Jacobson	Aug 2014	B2
8798762	Fain et al.	Aug 2014	B2
8798770	Reddy	Aug 2014	B2
8805505	Roberts	Aug 2014	B1
8805528	Corndorf	Aug 2014	B2
8812109	Blomqvist et al.	Aug 2014	B2
8818504	Bodner et al.	Aug 2014	B2
8827913	Havel et al.	Sep 2014	B2
8831721	Hettrick et al.	Sep 2014	B2
8831747	Min et al.	Sep 2014	B1
8843198	Lian et al.	Sep 2014	B2
8855789	Jacobson	Oct 2014	B2
8868186	Kroll	Oct 2014	B2
8886325	Boling et al.	Nov 2014	B2
8886339	Faltys et al.	Nov 2014	B2
8903473	Rogers et al.	Dec 2014	B2
8903500	Smith et al.	Dec 2014	B2
8903513	Ollivier	Dec 2014	B2
8909336	Navarro-Paredes et al.	Dec 2014	B2
8914131	Bornzin et al.	Dec 2014	B2
8923795	Makdissi et al.	Dec 2014	B2
8923963	Bonner et al.	Dec 2014	B2
8938300	Rosero	Jan 2015	B2
8942806	Sheldon et al.	Jan 2015	B2
8958892	Khairkhahan et al.	Feb 2015	B2
8977358	Ewert et al.	Mar 2015	B2
8989873	Locsin	Mar 2015	B2
8996109	Karst et al.	Mar 2015	B2
9002467	Smith et al.	Apr 2015	B2
9008776	Cowan et al.	Apr 2015	B2
9008777	Dianaty et al.	Apr 2015	B2
9014818	Deterre et al.	Apr 2015	B2
9017341	Bornzin et al.	Apr 2015	B2
9020611	Khairkhahan et al.	Apr 2015	B2
9037262	Regnier et al.	May 2015	B2
9042984	Demmer et al.	May 2015	B2
9072911	Hastings et al.	Jul 2015	B2
9072913	Jacobson	Jul 2015	B2
9072914	Greenhut et al.	Jul 2015	B2
9079035	Sanghera et al.	Jul 2015	B2
9155479	Solem	Oct 2015	B2
9155882	Grubac et al.	Oct 2015	B2
9168372	Fain	Oct 2015	B2
9168380	Greenhut et al.	Oct 2015	B1
9168383	Jacobson	Oct 2015	B2
9174062	Stadler et al.	Nov 2015	B2
9180285	Moore et al.	Nov 2015	B2
9192774	Jacobson	Nov 2015	B2
9199086	Zielinski et al.	Dec 2015	B2
9205225	Khairkhahan et al.	Dec 2015	B2
9216285	Boling et al.	Dec 2015	B1
9216293	Berthiaume et al.	Dec 2015	B2
9216298	Jacobson	Dec 2015	B2
9227077	Jacobson	Jan 2016	B2
9238145	Wenzel et al.	Jan 2016	B2
9242102	Khairkhahan et al.	Jan 2016	B2
9242113	Smith et al.	Jan 2016	B2
9248300	Rys et al.	Feb 2016	B2
9265436	Min et al.	Feb 2016	B2
9265954	Ghosh	Feb 2016	B2
9265955	Ghosh	Feb 2016	B2
9265962	Dianaty et al.	Feb 2016	B2
9272155	Ostroff	Mar 2016	B2
9278218	Karst et al.	Mar 2016	B2
9278229	Reinke et al.	Mar 2016	B1
9283381	Grubac et al.	Mar 2016	B2
9283382	Berthiaume et al.	Mar 2016	B2
9289612	Sambelashvili et al.	Mar 2016	B1
9302115	Molin et al.	Apr 2016	B2
9333364	Echt et al.	May 2016	B2
9358387	Suwito et al.	Jun 2016	B2
9358400	Jacobson	Jun 2016	B2
9364675	Deterre et al.	Jun 2016	B2
9370663	Moulder	Jun 2016	B2
9375580	Bonner et al.	Jun 2016	B2
9375581	Baru et al.	Jun 2016	B2
9381365	Kibler et al.	Jul 2016	B2
9393424	Demmer et al.	Jul 2016	B2
9393436	Doerr	Jul 2016	B2
9399139	Demmer et al.	Jul 2016	B2
9399140	Cho et al.	Jul 2016	B2
9409033	Jacobson	Aug 2016	B2
9427594	Bornzin et al.	Aug 2016	B1
9433368	Stahmann et al.	Sep 2016	B2
9433780	Régnier et al.	Sep 2016	B2
9457193	Klimovitch et al.	Oct 2016	B2
9492668	Sheldon et al.	Nov 2016	B2
9492669	Demmer et al.	Nov 2016	B2
9492674	Schmidt et al.	Nov 2016	B2
9492677	Greenhut et al.	Nov 2016	B2
9511233	Sambelashvili	Dec 2016	B2
9511236	Varady et al.	Dec 2016	B2
9511237	Deterre et al.	Dec 2016	B2
9522276	Shen et al.	Dec 2016	B2
9522280	Fishler et al.	Dec 2016	B2
9526522	Wood et al.	Dec 2016	B2
9526891	Eggen et al.	Dec 2016	B2
9526909	Stahmann et al.	Dec 2016	B2
9533163	Klimovitch et al.	Jan 2017	B2
9561382	Persson et al.	Feb 2017	B2
9566012	Greenhut et al.	Feb 2017	B2
9636511	Carney et al.	May 2017	B2
9669223	Auricchio et al.	Jun 2017	B2
9687654	Sheldon et al.	Jun 2017	B2
9687655	Pertijs et al.	Jun 2017	B2
9687659	Von Arx et al.	Jun 2017	B2
9694186	Carney et al.	Jul 2017	B2
9782594	Stahmann et al.	Oct 2017	B2
9782601	Ludwig	Oct 2017	B2
9789317	Greenhut et al.	Oct 2017	B2
9789319	Sambelashvili	Oct 2017	B2
9808617	Ostroff et al.	Nov 2017	B2
9808628	Sheldon et al.	Nov 2017	B2
9808631	Maile et al.	Nov 2017	B2
9808632	Reinke et al.	Nov 2017	B2
9808633	Bonner et al.	Nov 2017	B2
9808637	Sharma et al.	Nov 2017	B2
9855414	Marshall et al.	Jan 2018	B2
9855430	Ghosh et al.	Jan 2018	B2
9855435	Sahabi et al.	Jan 2018	B2
9861815	Tran et al.	Jan 2018	B2
10080887	Schmidt et al.	Sep 2018	B2
10080888	Kelly et al.	Sep 2018	B2
10080900	Ghosh et al.	Sep 2018	B2
10080903	Willis et al.	Sep 2018	B2
10086206	Sambelashvili	Oct 2018	B2
10118026	Grubac et al.	Nov 2018	B2
10124163	Ollivier et al.	Nov 2018	B2
10124175	Berthiaume et al.	Nov 2018	B2
10130821	Grubac et al.	Nov 2018	B2
10137305	Kane et al.	Nov 2018	B2
10201710	Jackson et al.	Feb 2019	B2
10207115	Echt et al.	Feb 2019	B2
10207116	Sheldon et al.	Feb 2019	B2
10226197	Reinke et al.	Mar 2019	B2
10226639	Zhang	Mar 2019	B2
10232182	Hareland et al.	Mar 2019	B2
10265503	Schmidt et al.	Apr 2019	B2
10265534	Greenhut et al.	Apr 2019	B2
10271752	Regnier et al.	Apr 2019	B2
10278601	Greenhut et al.	May 2019	B2
10279165	Seifert et al.	May 2019	B2
10286221	Sawchuk	May 2019	B2
10307598	Ciciarelli et al.	Jun 2019	B2
10328274	Zhang et al.	Jun 2019	B2
10342981	Ghosh et al.	Jul 2019	B2
10765871	Kane	Sep 2020	B2
11065459	Maile	Jul 2021	B2
20010012953	Molin et al.	Aug 2001	A1
20010021864	Molin	Sep 2001	A1
20010031995	Molin	Oct 2001	A1
20010034540	Molin	Oct 2001	A1
20010049543	Kroll	Dec 2001	A1
20020032470	Linberg	Mar 2002	A1
20020035376	Bardy et al.	Mar 2002	A1
20020035377	Bardy et al.	Mar 2002	A1
20020035378	Bardy et al.	Mar 2002	A1
20020035380	Rissmann et al.	Mar 2002	A1
20020035381	Bardy et al.	Mar 2002	A1
20020042629	Bardy et al.	Apr 2002	A1
20020042630	Bardy et al.	Apr 2002	A1
20020042634	Bardy et al.	Apr 2002	A1
20020049475	Bardy et al.	Apr 2002	A1
20020052636	Bardy et al.	May 2002	A1
20020068958	Bardy et al.	Jun 2002	A1
20020072773	Bardy et al.	Jun 2002	A1
20020082665	Haller et al.	Jun 2002	A1
20020087089	Ben Haim	Jul 2002	A1
20020091414	Bardy et al.	Jul 2002	A1
20020095196	Linberg	Jul 2002	A1
20020099423	Berg et al.	Jul 2002	A1
20020103510	Bardy et al.	Aug 2002	A1
20020107545	Rissmann et al.	Aug 2002	A1
20020107546	Ostroff et al.	Aug 2002	A1
20020107547	Erlinger et al.	Aug 2002	A1
20020107548	Bardy et al.	Aug 2002	A1
20020107549	Bardy et al.	Aug 2002	A1
20020107559	Sanders et al.	Aug 2002	A1
20020120299	Ostroff et al.	Aug 2002	A1
20020173830	Starkweather et al.	Nov 2002	A1
20020193846	Pool et al.	Dec 2002	A1
20030009203	Ebel et al.	Jan 2003	A1
20030028082	Thompson	Feb 2003	A1
20030040779	Engmark et al.	Feb 2003	A1
20030041866	Linberg et al.	Mar 2003	A1
20030045805	Sheldon et al.	Mar 2003	A1
20030088278	Bardy et al.	May 2003	A1
20030097153	Bardy et al.	May 2003	A1
20030105497	Zhu et al.	Jun 2003	A1
20030114908	Flach	Jun 2003	A1
20030144701	Mehra et al.	Jul 2003	A1
20030187460	Chin et al.	Oct 2003	A1
20030187461	Chin	Oct 2003	A1
20030204212	Burnes et al.	Oct 2003	A1
20040024435	Leckrone et al.	Feb 2004	A1
20040032957	Mansy et al.	Feb 2004	A1
20040068302	Rodgers et al.	Apr 2004	A1
20040087938	Leckrone et al.	May 2004	A1
20040088035	Guenst et al.	May 2004	A1
20040102830	Williams	May 2004	A1
20040127959	Amundson et al.	Jul 2004	A1
20040133242	Chapman et al.	Jul 2004	A1
20040147969	Mann et al.	Jul 2004	A1
20040147973	Hauser	Jul 2004	A1
20040167558	Igo et al.	Aug 2004	A1
20040167587	Thompson	Aug 2004	A1
20040172071	Bardy et al.	Sep 2004	A1
20040172077	Chinchoy	Sep 2004	A1
20040172104	Berg et al.	Sep 2004	A1
20040176817	Wahlstrand et al.	Sep 2004	A1
20040176818	Wahlstrand et al.	Sep 2004	A1
20040176830	Fang	Sep 2004	A1
20040186529	Bardy et al.	Sep 2004	A1
20040204673	Flaherty	Oct 2004	A1
20040210292	Bardy et al.	Oct 2004	A1
20040210293	Bardy et al.	Oct 2004	A1
20040210294	Bardy et al.	Oct 2004	A1
20040215308	Bardy et al.	Oct 2004	A1
20040220624	Ritscher et al.	Nov 2004	A1
20040220626	Wagner	Nov 2004	A1
20040220639	Mulligan et al.	Nov 2004	A1
20040230283	Prinzen et al.	Nov 2004	A1
20040249431	Ransbury et al.	Dec 2004	A1
20040260348	Bakken et al.	Dec 2004	A1
20040267303	Guenst	Dec 2004	A1
20050038481	Chinchoy et al.	Feb 2005	A1
20050061320	Lee et al.	Mar 2005	A1
20050070962	Echt et al.	Mar 2005	A1
20050102003	Grabek et al.	May 2005	A1
20050149138	Min et al.	Jul 2005	A1
20050165466	Morris et al.	Jul 2005	A1
20050182447	Schecter	Aug 2005	A1
20050182465	Ness	Aug 2005	A1
20050203410	Jenkins	Sep 2005	A1
20050283208	Von Arx et al.	Dec 2005	A1
20050288743	Ahn et al.	Dec 2005	A1
20060041281	Von Arx et al.	Feb 2006	A1
20060042830	Maghribi et al.	Mar 2006	A1
20060052829	Sun et al.	Mar 2006	A1
20060052830	Spinelli et al.	Mar 2006	A1
20060064135	Brockway	Mar 2006	A1
20060064149	Belacazar et al.	Mar 2006	A1
20060085039	Hastings et al.	Apr 2006	A1
20060085041	Hastings et al.	Apr 2006	A1
20060085042	Hastings et al.	Apr 2006	A1
20060095078	Tronnes	May 2006	A1
20060106442	Richardson et al.	May 2006	A1
20060116746	Chin	Jun 2006	A1
20060135999	Bodner et al.	Jun 2006	A1
20060136004	Cowan et al.	Jun 2006	A1
20060161061	Echt et al.	Jul 2006	A1
20060200002	Guenst	Sep 2006	A1
20060206151	Lu	Sep 2006	A1
20060212079	Routh et al.	Sep 2006	A1
20060241701	Markowitz et al.	Oct 2006	A1
20060241705	Neumann et al.	Oct 2006	A1
20060247672	Vidlund et al.	Nov 2006	A1
20060247707	Meyer et al.	Nov 2006	A1
20060259088	Pastore et al.	Nov 2006	A1
20060265018	Smith et al.	Nov 2006	A1
20060271119	Ni et al.	Nov 2006	A1
20070004979	Wojciechowicz et al.	Jan 2007	A1
20070016098	Kim et al.	Jan 2007	A1
20070027508	Cowan	Feb 2007	A1
20070049977	Von Arx et al.	Mar 2007	A1
20070055170	Lippert et al.	Mar 2007	A1
20070060961	Echt	Mar 2007	A1
20070078490	Cowan et al.	Apr 2007	A1
20070088394	Jacobson	Apr 2007	A1
20070088396	Jacobson	Apr 2007	A1
20070088397	Jacobson	Apr 2007	A1
20070088398	Jacobson	Apr 2007	A1
20070088405	Jacobson	Apr 2007	A1
20070093874	Chirife et al.	Apr 2007	A1
20070135882	Drasler et al.	Jun 2007	A1
20070135883	Drasler et al.	Jun 2007	A1
20070150037	Hastings et al.	Jun 2007	A1
20070150038	Hastings et al.	Jun 2007	A1
20070156190	Cinbis	Jul 2007	A1
20070156194	Wang	Jul 2007	A1
20070219525	Gelfand et al.	Sep 2007	A1
20070219590	Hastings et al.	Sep 2007	A1
20070225545	Ferrari	Sep 2007	A1
20070233206	Frikart et al.	Oct 2007	A1
20070239244	Morgan et al.	Oct 2007	A1
20070255376	Michels et al.	Nov 2007	A1
20070276444	Gelbart et al.	Nov 2007	A1
20070293900	Sheldon et al.	Dec 2007	A1
20070293904	Gelbart et al.	Dec 2007	A1
20080004663	Jorgenson	Jan 2008	A1
20080021505	Hastings et al.	Jan 2008	A1
20080021519	De Geest et al.	Jan 2008	A1
20080021532	Kveen et al.	Jan 2008	A1
20080065183	Whitehurst et al.	Mar 2008	A1
20080065185	Worley	Mar 2008	A1
20080071318	Brooke et al.	Mar 2008	A1
20080109054	Hastings et al.	May 2008	A1
20080119911	Rosero	May 2008	A1
20080130670	Kim et al.	Jun 2008	A1
20080154139	Shuros et al.	Jun 2008	A1
20080154322	Jackson et al.	Jun 2008	A1
20080195167	Ryan	Aug 2008	A1
20080228234	Stancer	Sep 2008	A1
20080234771	Chinchoy et al.	Sep 2008	A1
20080243217	Wildon	Oct 2008	A1
20080269814	Rosero	Oct 2008	A1
20080269816	Prakash et al.	Oct 2008	A1
20080269825	Chinchoy et al.	Oct 2008	A1
20080275518	Ghanem et al.	Nov 2008	A1
20080275519	Ghanem et al.	Nov 2008	A1
20080275522	Dong et al.	Nov 2008	A1
20080288039	Reddy	Nov 2008	A1
20080294208	Willis et al.	Nov 2008	A1
20080294210	Rosero	Nov 2008	A1
20080294229	Friedman et al.	Nov 2008	A1
20080306359	Zdeblick et al.	Dec 2008	A1
20090018599	Hastings et al.	Jan 2009	A1
20090024180	Kisker et al.	Jan 2009	A1
20090036941	Corbucci	Feb 2009	A1
20090048646	Katoozi et al.	Feb 2009	A1
20090062895	Stahmann et al.	Mar 2009	A1
20090082827	Kveen et al.	Mar 2009	A1
20090082828	Ostroff	Mar 2009	A1
20090088813	Brockway et al.	Apr 2009	A1
20090118783	Pantangay et al.	May 2009	A1
20090131907	Chin et al.	May 2009	A1
20090135886	Robertson et al.	May 2009	A1
20090143835	Pastore et al.	Jun 2009	A1
20090171404	Irani et al.	Jul 2009	A1
20090171408	Solem	Jul 2009	A1
20090171414	Kelly et al.	Jul 2009	A1
20090204163	Shuros et al.	Aug 2009	A1
20090204170	Hastings et al.	Aug 2009	A1
20090210024	M.	Aug 2009	A1
20090216292	Pless et al.	Aug 2009	A1
20090234407	Hastings et al.	Sep 2009	A1
20090234411	Sambelashvili et al.	Sep 2009	A1
20090264949	Dong et al.	Oct 2009	A1
20090266573	Engmark et al.	Oct 2009	A1
20090270937	Yonce et al.	Oct 2009	A1
20090275843	Karamanoglu	Nov 2009	A1
20090275998	Burnes et al.	Nov 2009	A1
20090275999	Burnes et al.	Nov 2009	A1
20090299447	Jensen et al.	Dec 2009	A1
20100013668	Kantervik	Jan 2010	A1
20100016911	Willis et al.	Jan 2010	A1
20100023085	Wu et al.	Jan 2010	A1
20100030061	Canfield et al.	Feb 2010	A1
20100030327	Chatel	Feb 2010	A1
20100042108	Hibino	Feb 2010	A1
20100056871	Govari et al.	Mar 2010	A1
20100063375	Kassab et al.	Mar 2010	A1
20100063562	Cowan et al.	Mar 2010	A1
20100069768	Min et al.	Mar 2010	A1
20100069983	Peacock, III et al.	Mar 2010	A1
20100094367	Sen	Apr 2010	A1
20100106213	Hilpisch et al.	Apr 2010	A1
20100113944	Min et al.	May 2010	A1
20100113945	Ryan	May 2010	A1
20100114209	Krause et al.	May 2010	A1
20100114214	Morelli et al.	May 2010	A1
20100125281	Jacobson et al.	May 2010	A1
20100168761	Kassab et al.	Jul 2010	A1
20100168819	Freeberg	Jul 2010	A1
20100198288	Ostroff	Aug 2010	A1
20100198304	Wang	Aug 2010	A1
20100217367	Belson	Aug 2010	A1
20100228308	Cowan et al.	Sep 2010	A1
20100234906	Koh	Sep 2010	A1
20100234924	Willis	Sep 2010	A1
20100241185	Mahapatra et al.	Sep 2010	A1
20100249729	Morris et al.	Sep 2010	A1
20100286744	Echt et al.	Nov 2010	A1
20100298841	Prinzen et al.	Nov 2010	A1
20100305635	Liu	Dec 2010	A1
20100305646	Schulte et al.	Dec 2010	A1
20100312309	Harding	Dec 2010	A1
20100317978	Maile	Dec 2010	A1
20100331905	Li et al.	Dec 2010	A1
20110022113	Zdeblick et al.	Jan 2011	A1
20110022127	Averina et al.	Jan 2011	A1
20110071586	Jacobson	Mar 2011	A1
20110077708	Ostroff	Mar 2011	A1
20110112600	Cowan et al.	May 2011	A1
20110118588	Komblau et al.	May 2011	A1
20110118810	Cowan et al.	May 2011	A1
20110125208	Karst et al.	May 2011	A1
20110137187	Yang et al.	Jun 2011	A1
20110144720	Cowan et al.	Jun 2011	A1
20110152970	Jollota et al.	Jun 2011	A1
20110160558	Rassatt et al.	Jun 2011	A1
20110160565	Stubbs et al.	Jun 2011	A1
20110160787	Greenhut et al.	Jun 2011	A1
20110160801	Markowitz et al.	Jun 2011	A1
20110160806	Lyden et al.	Jun 2011	A1
20110166620	Cowan et al.	Jul 2011	A1
20110166621	Cowan et al.	Jul 2011	A1
20110178567	Pei et al.	Jul 2011	A1
20110184491	Kivi	Jul 2011	A1
20110190835	Brockway et al.	Aug 2011	A1
20110208260	Jacobson	Aug 2011	A1
20110218587	Jacobson	Sep 2011	A1
20110230734	Fain et al.	Sep 2011	A1
20110237967	Moore et al.	Sep 2011	A1
20110245890	Brisben et al.	Oct 2011	A1
20110251660	Griswold	Oct 2011	A1
20110251662	Griswold et al.	Oct 2011	A1
20110270099	Ruben et al.	Nov 2011	A1
20110270339	Murray, III et al.	Nov 2011	A1
20110270340	Pellegrini et al.	Nov 2011	A1
20110270341	Ruben et al.	Nov 2011	A1
20110276102	Cohen	Nov 2011	A1
20110282423	Jacobson	Nov 2011	A1
20120004527	Thompson et al.	Jan 2012	A1
20120029323	Zhao	Feb 2012	A1
20120029335	Sudam et al.	Feb 2012	A1
20120041508	Rousso et al.	Feb 2012	A1
20120059433	Cowan et al.	Mar 2012	A1
20120059436	Fontaine et al.	Mar 2012	A1
20120065500	Rogers et al.	Mar 2012	A1
20120078322	Dal Molin et al.	Mar 2012	A1
20120089198	Ostroff	Apr 2012	A1
20120093245	Makdissi et al.	Apr 2012	A1
20120095521	Hintz	Apr 2012	A1
20120095539	Khairkhahan et al.	Apr 2012	A1
20120101540	O'Brien et al.	Apr 2012	A1
20120101553	Reddy	Apr 2012	A1
20120109148	Bonner et al.	May 2012	A1
20120109149	Bonner et al.	May 2012	A1
20120109236	Jacobson et al.	May 2012	A1
20120109259	Bond et al.	May 2012	A1
20120116489	Khairkhahan et al.	May 2012	A1
20120136406	Min	May 2012	A1
20120150251	Giftakis et al.	Jun 2012	A1
20120158111	Khairkhahan et al.	Jun 2012	A1
20120165692	Hollmark et al.	Jun 2012	A1
20120165827	Khairkhahan et al.	Jun 2012	A1
20120172690	Anderson et al.	Jul 2012	A1
20120172891	Lee	Jul 2012	A1
20120172892	Grubac et al.	Jul 2012	A1
20120172942	Berg	Jul 2012	A1
20120197350	Roberts et al.	Aug 2012	A1
20120197373	Khairkhahan et al.	Aug 2012	A1
20120215285	Tahmasian et al.	Aug 2012	A1
20120232565	Kveen et al.	Sep 2012	A1
20120245665	Friedman et al.	Sep 2012	A1
20120277600	Greenhut	Nov 2012	A1
20120277606	Ellingson et al.	Nov 2012	A1
20120283795	Stancer et al.	Nov 2012	A1
20120283807	Deterre et al.	Nov 2012	A1
20120289776	Keast et al.	Nov 2012	A1
20120289815	Keast et al.	Nov 2012	A1
20120290021	Saurkar et al.	Nov 2012	A1
20120290025	Keimel	Nov 2012	A1
20120296381	Matos	Nov 2012	A1
20120303082	Dong et al.	Nov 2012	A1
20120316613	Keefe et al.	Dec 2012	A1
20120330392	Regnier et al.	Dec 2012	A1
20130012151	Hankins	Jan 2013	A1
20130023975	Locsin	Jan 2013	A1
20130030484	Zhang et al.	Jan 2013	A1
20130035748	Bonner et al.	Feb 2013	A1
20130041422	Jacobson	Feb 2013	A1
20130053908	Smith et al.	Feb 2013	A1
20130053915	Holmstrom et al.	Feb 2013	A1
20130053921	Bonner et al.	Feb 2013	A1
20130060298	Splett et al.	Mar 2013	A1
20130066169	Rys et al.	Mar 2013	A1
20130072770	Rao et al.	Mar 2013	A1
20130079798	Tran et al.	Mar 2013	A1
20130079839	Lian et al.	Mar 2013	A1
20130079861	Reinert et al.	Mar 2013	A1
20130085350	Schugt et al.	Apr 2013	A1
20130085403	Gunderson et al.	Apr 2013	A1
20130085550	Polefko et al.	Apr 2013	A1
20130096649	Martin et al.	Apr 2013	A1
20130103047	Steingisser et al.	Apr 2013	A1
20130103109	Jacobson	Apr 2013	A1
20130110008	Bourget et al.	May 2013	A1
20130110127	Bornzin et al.	May 2013	A1
20130110192	Tran et al.	May 2013	A1
20130110219	Bornzin et al.	May 2013	A1
20130116529	Min et al.	May 2013	A1
20130116738	Samade et al.	May 2013	A1
20130116740	Bornzin et al.	May 2013	A1
20130116741	Bornzin et al.	May 2013	A1
20130123872	Bornzin et al.	May 2013	A1
20130123875	Varady et al.	May 2013	A1
20130131591	Berthiaume et al.	May 2013	A1
20130131693	Berthiaume et al.	May 2013	A1
20130138006	Bornzin et al.	May 2013	A1
20130150695	Biela et al.	Jun 2013	A1
20130150911	Perschbacher et al.	Jun 2013	A1
20130150912	Perschbacher et al.	Jun 2013	A1
20130184776	Shuros et al.	Jul 2013	A1
20130192611	Taepke, II et al.	Aug 2013	A1
20130196703	Masoud et al.	Aug 2013	A1
20130197609	Moore et al.	Aug 2013	A1
20130231710	Jacobson	Sep 2013	A1
20130238072	Deterre et al.	Sep 2013	A1
20130238073	Makdissi et al.	Sep 2013	A1
20130245709	Bohn et al.	Sep 2013	A1
20130253309	Allan et al.	Sep 2013	A1
20130253342	Griswold et al.	Sep 2013	A1
20130253343	Waldhauser et al.	Sep 2013	A1
20130253344	Griswold et al.	Sep 2013	A1
20130253345	Griswold et al.	Sep 2013	A1
20130253346	Griswold et al.	Sep 2013	A1
20130253347	Griswold et al.	Sep 2013	A1
20130261497	Pertijs et al.	Oct 2013	A1
20130265144	Banna et al.	Oct 2013	A1
20130268042	Hastings et al.	Oct 2013	A1
20130274828	Willis	Oct 2013	A1
20130274847	Ostroff	Oct 2013	A1
20130282070	Cowan et al.	Oct 2013	A1
20130282073	Cowan et al.	Oct 2013	A1
20130296727	Sullivan et al.	Nov 2013	A1
20130303872	Taff et al.	Nov 2013	A1
20130310890	Sweeney	Nov 2013	A1
20130324825	Ostroff et al.	Dec 2013	A1
20130325081	Karst et al.	Dec 2013	A1
20130345770	Dianaty et al.	Dec 2013	A1
20140012344	Hastings et al.	Jan 2014	A1
20140018876	Ostroff	Jan 2014	A1
20140018877	Demmer et al.	Jan 2014	A1
20140031836	Ollivier	Jan 2014	A1
20140039570	Carroll et al.	Feb 2014	A1
20140039591	Drasler et al.	Feb 2014	A1
20140043146	Makdissi et al.	Feb 2014	A1
20140046395	Regnier et al.	Feb 2014	A1
20140046420	Moore et al.	Feb 2014	A1
20140058240	Mothilal et al.	Feb 2014	A1
20140058494	Ostroff et al.	Feb 2014	A1
20140074114	Khairkhahan et al.	Mar 2014	A1
20140074186	Faltys et al.	Mar 2014	A1
20140094891	Pare et al.	Apr 2014	A1
20140100624	Ellingson	Apr 2014	A1
20140100627	Min	Apr 2014	A1
20140107723	Hou et al.	Apr 2014	A1
20140121719	Bonner et al.	May 2014	A1
20140121720	Bonner et al.	May 2014	A1
20140121722	Sheldon et al.	May 2014	A1
20140128935	Kumar et al.	May 2014	A1
20140135865	Hastings et al.	May 2014	A1
20140142648	Smith et al.	May 2014	A1
20140148675	Nordstrom et al.	May 2014	A1
20140148815	Wenzel et al.	May 2014	A1
20140155950	Hastings et al.	Jun 2014	A1
20140163631	Maskara et al.	Jun 2014	A1
20140169162	Romano et al.	Jun 2014	A1
20140172060	Bornzin et al.	Jun 2014	A1
20140180306	Grubac et al.	Jun 2014	A1
20140180366	Edlund	Jun 2014	A1
20140207013	Lian et al.	Jul 2014	A1
20140207149	Hastings et al.	Jul 2014	A1
20140207210	Willis et al.	Jul 2014	A1
20140213916	Doan et al.	Jul 2014	A1
20140214104	Greenhut et al.	Jul 2014	A1
20140222015	Keast et al.	Aug 2014	A1
20140222098	Baru et al.	Aug 2014	A1
20140222099	Sweeney	Aug 2014	A1
20140222109	Moulder	Aug 2014	A1
20140228913	Molin et al.	Aug 2014	A1
20140236172	Hastings et al.	Aug 2014	A1
20140236253	Ghosh et al.	Aug 2014	A1
20140243848	Auricchio et al.	Aug 2014	A1
20140255298	Cole et al.	Sep 2014	A1
20140257324	Fain	Sep 2014	A1
20140257422	Herken	Sep 2014	A1
20140257444	Cole et al.	Sep 2014	A1
20140276929	Foster et al.	Sep 2014	A1
20140277240	Maskara et al.	Sep 2014	A1
20140303704	Suwito et al.	Oct 2014	A1
20140309706	Jacobson	Oct 2014	A1
20140343348	Kaplan et al.	Nov 2014	A1
20140371818	Bond et al.	Dec 2014	A1
20140379041	Foster	Dec 2014	A1
20150025612	Haasl et al.	Jan 2015	A1
20150032173	Ghosh	Jan 2015	A1
20150039041	Smith et al.	Feb 2015	A1
20150045868	Bonner et al.	Feb 2015	A1
20150051609	Schmidt et al.	Feb 2015	A1
20150051610	Schmidt et al.	Feb 2015	A1
20150051611	Schmidt et al.	Feb 2015	A1
20150051612	Schmidt et al.	Feb 2015	A1
20150051613	Schmidt et al.	Feb 2015	A1
20150051614	Schmidt et al.	Feb 2015	A1
20150051615	Schmidt et al.	Feb 2015	A1
20150051616	Haasl et al.	Feb 2015	A1
20150051682	Schmidt et al.	Feb 2015	A1
20150057520	Foster et al.	Feb 2015	A1
20150057558	Stahmann et al.	Feb 2015	A1
20150057721	Stahmann et al.	Feb 2015	A1
20150088155	Stahmann et al.	Mar 2015	A1
20150091415	Deterre et al.	Apr 2015	A1
20150105836	Bonner et al.	Apr 2015	A1
20150126854	Keast et al.	May 2015	A1
20150142069	Sambelashvili	May 2015	A1
20150142070	Sambelashvili	May 2015	A1
20150157861	Aghassian	Jun 2015	A1
20150157866	Demmer et al.	Jun 2015	A1
20150165199	Karst et al.	Jun 2015	A1
20150173655	Demmer et al.	Jun 2015	A1
20150182751	Ghosh et al.	Jul 2015	A1
20150190638	Smith et al.	Jul 2015	A1
20150196756	Stahmann et al.	Jul 2015	A1
20150196757	Stahmann et al.	Jul 2015	A1
20150196758	Stahmann et al.	Jul 2015	A1
20150196769	Stahmann et al.	Jul 2015	A1
20150202443	Zielinski et al.	Jul 2015	A1
20150217119	Nikolski et al.	Aug 2015	A1
20150217123	Deterre et al.	Aug 2015	A1
20150221898	Chi et al.	Aug 2015	A1
20150224315	Stahmann	Aug 2015	A1
20150224320	Stahmann	Aug 2015	A1
20150230699	Berul et al.	Aug 2015	A1
20150238769	Demmer et al.	Aug 2015	A1
20150258345	Smith et al.	Sep 2015	A1
20150290468	Zhang	Oct 2015	A1
20150297902	Stahmann et al.	Oct 2015	A1
20150297905	Greenhut et al.	Oct 2015	A1
20150297907	Zhang	Oct 2015	A1
20150305637	Greenhut et al.	Oct 2015	A1
20150305638	Zhang	Oct 2015	A1
20150305639	Greenhut et al.	Oct 2015	A1
20150305640	Reinke et al.	Oct 2015	A1
20150305641	Stadler et al.	Oct 2015	A1
20150305642	Reinke et al.	Oct 2015	A1
20150306374	Seifert et al.	Oct 2015	A1
20150306375	Marshall et al.	Oct 2015	A1
20150306401	Demmer et al.	Oct 2015	A1
20150306406	Crutchfield et al.	Oct 2015	A1
20150306407	Crutchfield et al.	Oct 2015	A1
20150306408	Greenhut et al.	Oct 2015	A1
20150321016	O'Brien et al.	Nov 2015	A1
20150328459	Chin et al.	Nov 2015	A1
20150335884	Khairkhahan et al.	Nov 2015	A1
20150360036	Kane et al.	Dec 2015	A1
20150367135	Whittington et al.	Dec 2015	A1
20160007873	Huelskamp et al.	Jan 2016	A1
20160015322	Anderson et al.	Jan 2016	A1
20160023000	Cho et al.	Jan 2016	A1
20160030757	Jacobson	Feb 2016	A1
20160033177	Barot et al.	Feb 2016	A1
20160038742	Stahmann et al.	Feb 2016	A1
20160045131	Siejko	Feb 2016	A1
20160045132	Siejko	Feb 2016	A1
20160045136	Siejko et al.	Feb 2016	A1
20160059007	Koop	Mar 2016	A1
20160059022	Stahmann et al.	Mar 2016	A1
20160059024	Stahmann et al.	Mar 2016	A1
20160059025	Stahmann et al.	Mar 2016	A1
20160067486	Brown et al.	Mar 2016	A1
20160067490	Carney et al.	Mar 2016	A1
20160089539	Gilkerson et al.	Mar 2016	A1
20160121127	Klimovitch	May 2016	A1
20160121128	Fishler et al.	May 2016	A1
20160121129	Persson et al.	May 2016	A1
20160129262	Sheldon et al.	May 2016	A1
20160144190	Cao et al.	May 2016	A1
20160151621	Maile et al.	Jun 2016	A1
20160175601	Nabutovsky et al.	Jun 2016	A1
20160213919	Suwito et al.	Jul 2016	A1
20160213937	Reinke et al.	Jul 2016	A1
20160213939	Carney et al.	Jul 2016	A1
20160228026	Jackson	Aug 2016	A1
20160256694	Shuros	Sep 2016	A1
20160271406	Maile et al.	Sep 2016	A1
20160277097	Ludwig et al.	Sep 2016	A1
20160296131	An et al.	Oct 2016	A1
20160310723	Eggen et al.	Oct 2016	A1
20160317825	Jacobson	Nov 2016	A1
20160367823	Cowan et al.	Dec 2016	A1
20170014629	Ghosh et al.	Jan 2017	A1
20170021159	Reddy et al.	Jan 2017	A1
20170035315	Jackson	Feb 2017	A1
20170043173	Sharma et al.	Feb 2017	A1
20170043174	Greenhut et al.	Feb 2017	A1
20170056665	Kane	Mar 2017	A1
20170056666	Kane et al.	Mar 2017	A1
20170105635	Cho	Apr 2017	A1
20170112390	Cho et al.	Apr 2017	A1
20170112399	Brisben et al.	Apr 2017	A1
20170113040	Brisben et al.	Apr 2017	A1
20170113050	Brisben et al.	Apr 2017	A1
20170113053	Brisben et al.	Apr 2017	A1
20170156617	Allavatan et al.	Jun 2017	A1
20170189681	Anderson	Jul 2017	A1
20170281261	Shuros et al.	Oct 2017	A1
20170281952	Shuros et al.	Oct 2017	A1
20170281953	Min et al.	Oct 2017	A1
20170281955	Maile et al.	Oct 2017	A1
20170312531	Sawchuk	Nov 2017	A1
20170368360	Hahn et al.	Dec 2017	A1
20180008829	An et al.	Jan 2018	A1
20180008831	An et al.	Jan 2018	A1
20180021567	An et al.	Jan 2018	A1
20180021581	An et al.	Jan 2018	A1
20180021582	An et al.	Jan 2018	A1
20180021584	An et al.	Jan 2018	A1
20180036527	Reddy et al.	Feb 2018	A1
20180056075	Hahn et al.	Mar 2018	A1
20180056079	Hahn et al.	Mar 2018	A1
20180078773	Thakur et al.	Mar 2018	A1
20180116593	An et al.	May 2018	A1
20180256902	Toy et al.	Sep 2018	A1
20180256909	Smith et al.	Sep 2018	A1
20180264262	Haasl et al.	Sep 2018	A1
20180264270	Koop et al.	Sep 2018	A1
20180264272	Haasl et al.	Sep 2018	A1
20180264273	Haasl et al.	Sep 2018	A1
20180264274	Haasl et al.	Sep 2018	A1
20180339160	Carroll	Nov 2018	A1

Foreign Referenced Citations (61)

Number	Date	Country
2008279789	Oct 2011	AU
2008329620	May 2014	AU
2014203793	Jul 2014	AU
1003904	Jan 1977	CA
202933393	May 2013	CN
0362611	Apr 1990	EP
503823	Sep 1992	EP
1702648	Sep 2006	EP
1904166	Jun 2011	EP
2471449	Jul 2012	EP
2471452	Jul 2012	EP
2433675	Jan 2013	EP
2441491	Jan 2013	EP
2452721	Nov 2013	EP
2662113	Nov 2013	EP
1948296	Jan 2014	EP
2280759	May 2015	EP
2760541	May 2016	EP
2833966	May 2016	EP
2000051373	Feb 2000	JP
2002502640	Jan 2002	JP
2004512105	Apr 2004	JP
2005508208	Mar 2005	JP
2005245215	Sep 2005	JP
2008540040	Nov 2008	JP
5199867	Feb 2013	JP
9407567	Apr 1994	WO
9500202	Jan 1995	WO
9636134	Nov 1996	WO
9724981	Jul 1997	WO
9826840	Jun 1998	WO
9939767	Aug 1999	WO
0234330	May 2002	WO
02098282	Dec 2002	WO
2003051457	Jun 2003	WO
2004078254	Sep 2004	WO
2005000206	Jan 2005	WO
2005018740	Mar 2005	WO
2005042089	May 2005	WO
2006065394	Jun 2006	WO
2006069215	Jun 2006	WO
2006086435	Aug 2006	WO
2006113659	Oct 2006	WO
2006124833	Nov 2006	WO
2007073435	Jun 2007	WO
2007075974	Jul 2007	WO
2007033094	Oct 2007	WO
2008034005	Mar 2008	WO
2009006531	Jan 2009	WO
2009025734	Feb 2009	WO
2009131768	Oct 2009	WO
2010088687	Aug 2010	WO
2012054102	Apr 2012	WO
2013003754	Jan 2013	WO
2013080038	Jun 2013	WO
2013098644	Jul 2013	WO
2013184787	Dec 2013	WO
2014120769	Aug 2014	WO
2014178035	Nov 2014	WO
2016022397	Feb 2016	WO
2016118735	Jul 2016	WO

Non-Patent Literature Citations (15)

Entry
US 8,886,318 B2, 11/2014, Jacobson et al. (withdrawn)
International Search Report and Written Opinion dated Sep. 6, 2017 for International Application No. PCT/US2017/039726.
Liang, “Piezoelectric Pressure Sensors Based on Flexible PZT Thick Film Composite Device,” University of Pittsburgh, 2014, 97 pages.
International Search Report and Written Opinion for Application No. PCT/US2017/057929, 12 pages, date mailed Jan. 26, 2018.
International Search Report and Written Opinion dated Oct. 5, 2017 for International Application No. PCT/US2017/037961.
International Search Report and Written Opinion for Application No. PCT/US2017/041562, 12 pages, date mailed Nov. 30, 2017.
Ginks et al; “Relationship between intracardiac impedance and left Ventricular contactility in patients undergoing cardiac resynchronization,” Europace, vol. 13, 984-991, 2001.
MPVS Ultra, “Complete PV Loop Analysis”, Pressure-Volume Loop Systems, Millar, downloaded Nov. 2017.
Roest et al; Prediction of long-term outcome of cardiac resynchronization therapy by acute pressure-vol. loop measurements, European Journal of Heart Failure, 15, 299-307, 2013.
“Complete PV Loop Analysis,” Millar, pp. 1-4, 2014.
“Instructions for Use System 1, Leadless Cardiac Pacemaker (LCP) and Delivery Catheter,” Nanostim Leadless Pacemakers, pp. 1-28, 2013.
Hachisuka et al., “Development and Performance Analysis of an Intra-Body Communication Device,” The 12th International Conference on Solid State Sensors, Actuators and Microsystems, vol. 4A1.3, pp. 1722-1725, 2003.
Seyedi et al., “A Survey on Intrabody Communications for Body Area Network Application,” IEEE Transactions on Biomedical Engineering, vol. 60(8): 2067-2079, 2013.
Spickler et al., “Totally Self-Contained Intracardiac Pacemaker,” Journal of Electrocardiology, vol. 3(3&4): 324-331, 1970.
Wegmüller, “Intra-Body Communication for Biomedical Sensor Networks,” Diss. ETH, No. 17323, 1-173, 2007.

Related Publications (1)

	Number	Date	Country
	20210308467 A1	Oct 2021	US

Provisional Applications (1)

	Number	Date	Country
	62547458	Aug 2017	US

Continuations (1)

	Number	Date	Country
Parent	16104370	Aug 2018	US
Child	17348957		US

Implantable medical device with pressure sensor

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Disclaimer

Term Extension

Abstract

Description

Claims

Parent Case Info

US Referenced Citations (1339)

Foreign Referenced Citations (61)

Non-Patent Literature Citations (15)

Related Publications (1)

Provisional Applications (1)

Continuations (1)